ID   POL_HV1H2               Reviewed;        1435 AA.
AC   P04585; O09777; Q9WJC5;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   22-JUL-2015, entry version 193.
DE   RecName: Full=Gag-Pol polyprotein;
DE   AltName: Full=Pr160Gag-Pol;
DE   Contains:
DE     RecName: Full=Matrix protein p17;
DE              Short=MA;
DE   Contains:
DE     RecName: Full=Capsid protein p24;
DE              Short=CA;
DE   Contains:
DE     RecName: Full=Spacer peptide 1 {ECO:0000250|UniProtKB:P12497};
DE              Short=SP1;
DE     AltName: Full=p2;
DE   Contains:
DE     RecName: Full=Nucleocapsid protein p7;
DE              Short=NC;
DE   Contains:
DE     RecName: Full=Transframe peptide;
DE              Short=TF;
DE   Contains:
DE     RecName: Full=p6-pol;
DE              Short=p6*;
DE   Contains:
DE     RecName: Full=Protease;
DE              EC=3.4.23.16;
DE     AltName: Full=PR;
DE     AltName: Full=Retropepsin;
DE   Contains:
DE     RecName: Full=Reverse transcriptase/ribonuclease H;
DE              EC=2.7.7.49;
DE              EC=2.7.7.7;
DE              EC=3.1.26.13;
DE     AltName: Full=Exoribonuclease H;
DE              EC=3.1.13.2;
DE     AltName: Full=p66 RT;
DE   Contains:
DE     RecName: Full=p51 RT;
DE   Contains:
DE     RecName: Full=p15;
DE   Contains:
DE     RecName: Full=Integrase;
DE              Short=IN;
GN   Name=gag-pol;
OS   Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)
OS   (HIV-1).
OC   Viruses; Retro-transcribing viruses; Retroviridae; Orthoretrovirinae;
OC   Lentivirus; Primate lentivirus group.
OX   NCBI_TaxID=11706;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=3040055; DOI=10.1089/aid.1987.3.57;
RA   Ratner L., Fisher A., Jagodzinski L.L., Mitsuya H., Liou R.-S.,
RA   Gallo R.C., Wong-Staal F.;
RT   "Complete nucleotide sequences of functional clones of the AIDS
RT   virus.";
RL   AIDS Res. Hum. Retroviruses 3:57-69(1987).
RN   [2]
RP   SEQUENCE REVISION.
RA   Ogata N., Alter H.J., Miller R.H., Purcell R.H.;
RL   Submitted (JUN-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RA   Chappey C.;
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   DIMERIZATION (PROTEASE).
RX   PubMed=2162350;
RA   Weber I.T.;
RT   "Comparison of the crystal structures and intersubunit interactions of
RT   human immunodeficiency and Rous sarcoma virus proteases.";
RL   J. Biol. Chem. 265:10492-10496(1990).
RN   [5]
RP   MUTAGENESIS OF HIS-1159; HIS-1163; GLN-1200; ASP-1211; SER-1228;
RP   ASP-1263; GLU-1299; ARG-1346 AND TRP-1382.
RX   PubMed=8420982;
RA   Leavitt A.D., Shiue L., Varmus H.E.;
RT   "Site-directed mutagenesis of HIV-1 integrase demonstrates
RT   differential effects on integrase functions in vitro.";
RL   J. Biol. Chem. 268:2113-2119(1993).
RN   [6]
RP   MUTAGENESIS OF CYS-1187; CYS-1190; TRP-1208; ASP-1211; THR-1213;
RP   VAL-1222; SER-1228; THR-1262; ASP-1263; GLY-1270; ILE-1282; VAL-1298;
RP   GLU-1299; LYS-1306; ALA-1326 AND TRP-1382.
RC   STRAIN=Isolate WI3;
RX   PubMed=8035478;
RA   Cannon P.M., Wilson W., Byles E., Kingsman S.M., Kingsman A.J.;
RT   "Human immunodeficiency virus type 1 integrase: effect on viral
RT   replication of mutations at highly conserved residues.";
RL   J. Virol. 68:4768-4775(1994).
RN   [7]
RP   INTERACTION OF CAPSID WITH HUMAN PPIA/CYPA.
RX   PubMed=8513493; DOI=10.1016/0092-8674(93)90637-6;
RA   Luban J., Bossolt K.L., Franke E.K., Kalpana G.V., Goff S.P.;
RT   "Human immunodeficiency virus type 1 Gag protein binds to cyclophilins
RT   A and B.";
RL   Cell 73:1067-1078(1993).
RN   [8]
RP   INTERACTION OF INTEGRASE WITH HUMAN SMARCB1/INI1.
RX   PubMed=7801128; DOI=10.1126/science.7801128;
RA   Kalpana G.V., Marmon S., Wang W., Crabtree G.R., Goff S.P.;
RT   "Binding and stimulation of HIV-1 integrase by a human homolog of
RT   yeast transcription factor SNF5.";
RL   Science 266:2002-2006(1994).
RN   [9]
RP   FUNCTION (PROTEASE).
RX   PubMed=7835426; DOI=10.1016/0014-5793(94)01370-G;
RA   Gaedigk-Nitschko K., Schoen A., Wachinger G., Erfle V., Kohleisen B.;
RT   "Cleavage of recombinant and cell derived human immunodeficiency virus
RT   1 (HIV-1) Nef protein by HIV-1 protease.";
RL   FEBS Lett. 357:275-278(1995).
RN   [10]
RP   FUNCTION (CAPSID PROTEIN P24).
RX   PubMed=8648689;
RA   Braaten D., Franke E.K., Luban J.;
RT   "Cyclophilin A is required for an early step in the life cycle of
RT   human immunodeficiency virus type 1 before the initiation of reverse
RT   transcription.";
RL   J. Virol. 70:3551-3560(1996).
RN   [11]
RP   MUTAGENESIS OF PRO-217; VAL-218; HIS-219; ALA-220; GLY-221; PRO-222;
RP   ILE-223; ALA-224 AND PRO-225, AND INTERACTION WITH HUMAN CYPA.
RX   PubMed=9223641; DOI=10.1006/jmbi.1997.1051;
RA   Yoo S., Myszka D.G., Yeh C., McMurray M., Hill C.P., Sundquist W.I.;
RT   "Molecular recognition in the HIV-1 capsid/cyclophilin A complex.";
RL   J. Mol. Biol. 269:780-795(1997).
RN   [12]
RP   MUTAGENESIS OF ASP-1211; ASP-1263 AND GLU-1299.
RX   PubMed=9573231;
RA   Gaur M., Leavitt A.D.;
RT   "Mutations in the human immunodeficiency virus type 1 integrase
RT   D,D(35)E motif do not eliminate provirus formation.";
RL   J. Virol. 72:4678-4685(1998).
RN   [13]
RP   MUTAGENESIS OF LYS-18; ARG-22 AND LYS-27.
RX   PubMed=10604476; DOI=10.1038/45272;
RA   Dupont S., Sharova N., DeHoratius C., Virbasius C.M., Zhu X.,
RA   Bukrinskaya A.G., Stevenson M., Green M.R.;
RT   "A novel nuclear export activity in HIV-1 matrix protein required for
RT   viral replication.";
RL   Nature 402:681-685(1999).
RN   [14]
RP   PROTEOLYTIC PROCESSING OF POLYPROTEIN.
RX   PubMed=10494040; DOI=10.1007/BF02253522;
RA   Chang Y.Y., Yu S.L., Syu W.J.;
RT   "Organization of HIV-1 pol is critical for Pol polyprotein
RT   processing.";
RL   J. Biomed. Sci. 6:333-341(1999).
RN   [15]
RP   FUNCTION (NUCLEOCAPSID PROTEIN P7).
RX   PubMed=9931246; DOI=10.1006/jmbi.1998.2460;
RA   Negroni M., Buc H.;
RT   "Recombination during reverse transcription: an evaluation of the role
RT   of the nucleocapsid protein.";
RL   J. Mol. Biol. 286:15-31(1999).
RN   [16]
RP   FUNCTION (NUCLEOCAPSID PROTEIN P7).
RX   PubMed=11044125; DOI=10.1128/JVI.74.22.10796-10800.2000;
RA   Cen S., Khorchid A., Gabor J., Rong L., Wainberg M.A., Kleiman L.;
RT   "Roles of Pr55(gag) and NCp7 in tRNA(3)(Lys) genomic placement and the
RT   initiation step of reverse transcription in human immunodeficiency
RT   virus type 1.";
RL   J. Virol. 74:10796-10800(2000).
RN   [17]
RP   GAG/GAG-POL RATIO.
RX   PubMed=11160682; DOI=10.1128/JVI.75.4.1834-1841.2001;
RA   Shehu-Xhilaga M., Crowe S.M., Mak J.;
RT   "Maintenance of the Gag/Gag-Pol ratio is important for human
RT   immunodeficiency virus type 1 RNA dimerization and viral
RT   infectivity.";
RL   J. Virol. 75:1834-1841(2001).
RN   [18]
RP   ACTIVE SITES (REVERSE TRANSCRIPTASE/RIBONUCLEASE H), AND MUTAGENESIS
RP   OF GLU-1065 AND ASP-1136.
RX   PubMed=12206668; DOI=10.1021/bi025871v;
RA   Cristofaro J.V., Rausch J.W., Le Grice S.F., DeStefano J.J.;
RT   "Mutations in the ribonuclease H active site of HIV-RT reveal a role
RT   for this site in stabilizing enzyme-primer-template binding.";
RL   Biochemistry 41:10968-10975(2002).
RN   [19]
RP   CIS/TRANS ISOMERIZATION (CAPSID PROTEIN P24).
RX   PubMed=11929983; DOI=10.1073/pnas.082100499;
RA   Bosco D.A., Eisenmesser E.Z., Pochapsky S., Sundquist W.I., Kern D.;
RT   "Catalysis of cis/trans isomerization in native HIV-1 capsid by human
RT   cyclophilin A.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:5247-5252(2002).
RN   [20]
RP   MUTAGENESIS OF HIS-400; CYS-405; HIS-421 AND CYS-426.
RX   PubMed=11932404; DOI=10.1128/JVI.76.9.4370-4378.2002;
RA   Guo J., Wu T., Kane B.F., Johnson D.G., Henderson L.E., Gorelick R.J.,
RA   Levin J.G.;
RT   "Subtle alterations of the native zinc finger structures have dramatic
RT   effects on the nucleic acid chaperone activity of human
RT   immunodeficiency virus type 1 nucleocapsid protein.";
RL   J. Virol. 76:4370-4378(2002).
RN   [21]
RP   PROTEOLYTIC PROCESSING (GAG-POL POLYPROTEIN).
RX   PubMed=12477841; DOI=10.1128/JVI.77.1.366-374.2003;
RA   Pettit S.C., Gulnik S., Everitt L., Kaplan A.H.;
RT   "The dimer interfaces of protease and extra-protease domains influence
RT   the activation of protease and the specificity of GagPol cleavage.";
RL   J. Virol. 77:366-374(2003).
RN   [22]
RP   QUARTERNARY STRUCTURE (CAPSID PROTEIN P24).
RX   PubMed=12660176; DOI=10.1093/emboj/cdg143;
RA   Briggs J.A., Wilk T., Welker R., Krausslich H.G., Fuller S.D.;
RT   "Structural organization of authentic, mature HIV-1 virions and
RT   cores.";
RL   EMBO J. 22:1707-1715(2003).
RN   [23]
RP   FUNCTION (PROTEASE).
RX   PubMed=12505164; DOI=10.1016/S0014-5793(02)03764-X;
RA   Perales C., Carrasco L., Ventoso I.;
RT   "Cleavage of eIF4G by HIV-1 protease: effects on translation.";
RL   FEBS Lett. 533:89-94(2003).
RN   [24]
RP   CLEAVAGE (NUCLEOCAPSID PROTEIN P7).
RX   PubMed=15065874; DOI=10.1021/bi035625z;
RA   Tozser J., Shulenin S., Louis J.M., Copeland T.D., Oroszlan S.;
RT   "In vitro processing of HIV-1 nucleocapsid protein by the viral
RT   proteinase: effects of amino acid substitutions at the scissile bond
RT   in the proximal zinc finger sequence.";
RL   Biochemistry 43:4304-4312(2004).
RN   [25]
RP   FUNCTION (REVERSE TRANSCRIPTASE/RIBONUCLEASE H).
RX   PubMed=16221683; DOI=10.1074/jbc.M507839200;
RA   Purohit V., Balakrishnan M., Kim B., Bambara R.A.;
RT   "Evidence that HIV-1 reverse transcriptase employs the DNA 3' end
RT   directed primary/secondary RNase H cleavage mechanism during synthesis
RT   and strand transfer.";
RL   J. Biol. Chem. 280:40534-40543(2005).
RN   [26]
RP   MUTAGENESIS OF ASN-394.
RX   PubMed=16904152; DOI=10.1016/j.virol.2006.07.011;
RA   Thomas J.A., Shulenin S., Coren L.V., Bosche W.J., Gagliardi T.D.,
RA   Gorelick R.J., Oroszlan S.;
RT   "Characterization of human immunodeficiency virus type 1 (HIV-1)
RT   containing mutations in the nucleocapsid protein at a putative HIV-1
RT   protease cleavage site.";
RL   Virology 354:261-270(2006).
RN   [27]
RP   FUNCTION (NUCLEOCAPSID PROTEIN P7).
RX   PubMed=17070549; DOI=10.1016/j.jmb.2006.09.081;
RA   Hagan N.A., Fabris D.;
RT   "Dissecting the protein-RNA and RNA-RNA interactions in the
RT   nucleocapsid-mediated dimerization and isomerization of HIV-1 stemloop
RT   1.";
RL   J. Mol. Biol. 365:396-410(2007).
RN   [28]
RP   SUBUNIT (MATRIX PROTEIN P17).
RX   PubMed=17108052; DOI=10.1128/JVI.02122-06;
RA   Alfadhli A., Huseby D., Kapit E., Colman D., Barklis E.;
RT   "Human immunodeficiency virus type 1 matrix protein assembles on
RT   membranes as a hexamer.";
RL   J. Virol. 81:1472-1478(2007).
RN   [29]
RP   MUTAGENESIS OF SER-6; SER-9; SER-67 AND SER-72, AND
RP   POST-TRANSRCRIPTIONAL MODIFICATION.
RX   PubMed=17656588; DOI=10.1110/ps.072987607;
RA   Saad J.S., Kim A., Ghanam R.H., Dalton A.K., Vogt V.M., Wu Z., Lu W.,
RA   Summers M.F.;
RT   "Mutations that mimic phosphorylation of the HIV-1 matrix protein do
RT   not perturb the myristyl switch.";
RL   Protein Sci. 16:1793-1797(2007).
RN   [30]
RP   FUNCTION (NUCLEOCAPSID PROTEIN P7).
RX   PubMed=18343475; DOI=10.1016/j.virol.2008.02.001;
RA   Kafaie J., Song R., Abrahamyan L., Mouland A.J., Laughrea M.;
RT   "Mapping of nucleocapsid residues important for HIV-1 genomic RNA
RT   dimerization and packaging.";
RL   Virology 375:592-610(2008).
RN   [31]
RP   SUBUNIT (CAPSID PROTEIN P24), AND FUNCTION (CAPSID PROTEIN P24).
RX   PubMed=19914170; DOI=10.1016/j.cell.2009.10.010;
RA   Byeon I.J., Meng X., Jung J., Zhao G., Yang R., Ahn J., Shi J.,
RA   Concel J., Aiken C., Zhang P., Gronenborn A.M.;
RT   "Structural convergence between Cryo-EM and NMR reveals intersubunit
RT   interactions critical for HIV-1 capsid function.";
RL   Cell 139:780-790(2009).
RN   [32]
RP   FUNCTION (PROTEASE).
RX   PubMed=19956697; DOI=10.1371/journal.pone.0007997;
RA   Castello A., Franco D., Moral-Lopez P., Berlanga J.J., Alvarez E.,
RA   Wimmer E., Carrasco L.;
RT   "HIV- 1 protease inhibits Cap- and poly(A)-dependent translation upon
RT   eIF4GI and PABP cleavage.";
RL   PLoS ONE 4:E7997-E7997(2009).
RN   [33]
RP   SUBUNIT (MATRIX PROTEIN P17).
RX   PubMed=19327811; DOI=10.1016/j.virol.2009.02.048;
RA   Alfadhli A., Barklis R.L., Barklis E.;
RT   "HIV-1 matrix organizes as a hexamer of trimers on membranes
RT   containing phosphatidylinositol-(4,5)-bisphosphate.";
RL   Virology 387:466-472(2009).
RN   [34]
RP   INTERACTION OF GAG POLYPROTEIN WITH PDZD8.
RX   PubMed=20573829; DOI=10.1128/JVI.00843-10;
RA   Henning M.S., Morham S.G., Goff S.P., Naghavi M.H.;
RT   "PDZD8 is a novel Gag-interacting factor that promotes retroviral
RT   infection.";
RL   J. Virol. 84:8990-8995(2010).
RN   [35]
RP   FUNCTION (INTEGRASE), AND INTERACTION OF INTEGRASE WITH HUMAN KPNA3.
RX   PubMed=20554775; DOI=10.1128/JVI.00508-10;
RA   Ao Z., Danappa Jayappa K., Wang B., Zheng Y., Kung S., Rassart E.,
RA   Depping R., Kohler M., Cohen E.A., Yao X.;
RT   "Importin alpha3 interacts with HIV-1 integrase and contributes to
RT   HIV-1 nuclear import and replication.";
RL   J. Virol. 84:8650-8663(2010).
RN   [36]
RP   FUNCTION (NUCLEOCAPSID PROTEIN P7).
RX   PubMed=20828778; DOI=10.1016/j.virol.2010.08.013;
RA   Jalalirad M., Laughrea M.;
RT   "Formation of immature and mature genomic RNA dimers in wild-type and
RT   protease-inactive HIV-1: differential roles of the Gag polyprotein,
RT   nucleocapsid proteins NCp15, NCp9, NCp7, and the dimerization
RT   initiation site.";
RL   Virology 407:225-236(2010).
RN   [37]
RP   INTERACTION WITH MONKEY TRIM5.
RX   PubMed=23785198; DOI=10.1128/JVI.00713-13;
RA   Shi J., Friedman D.B., Aiken C.;
RT   "Retrovirus restriction by TRIM5 proteins requires recognition of only
RT   a small fraction of viral capsid subunits.";
RL   J. Virol. 87:9271-9278(2013).
RN   [38]
RP   DIMERIZATION (PROTEASE).
RX   PubMed=24132393; DOI=10.1007/s10930-013-9517-y;
RA   Naicker P., Seele P., Dirr H.W., Sayed Y.;
RT   "F99 is critical for dimerization and activation of South African HIV-
RT   1 subtype C protease.";
RL   Protein J. 32:560-567(2013).
RN   [39]
RP   INTERACTION OF CAPSID-NUCLEOCAPSID COMPLEX WITH HUMAN PDZD8.
RX   PubMed=24554657; DOI=10.1128/JVI.02945-13;
RA   Guth C.A., Sodroski J.;
RT   "Contribution of PDZD8 to stabilization of the human immunodeficiency
RT   virus type 1 capsid.";
RL   J. Virol. 88:4612-4623(2014).
RN   [40]
RP   INTERACTION OF MATRIX PROTEIN P17 WITH RAT CALM1.
RX   PubMed=24500712; DOI=10.1074/jbc.M113.543694;
RA   Vlach J., Samal A.B., Saad J.S.;
RT   "Solution structure of calmodulin bound to the binding domain of the
RT   HIV-1 matrix protein.";
RL   J. Biol. Chem. 289:8697-8705(2014).
RN   [41]
RP   REVIEW.
RX   PubMed=8791726;
RA   Vogt V.M.;
RT   "Proteolytic processing and particle maturation.";
RL   Curr. Top. Microbiol. Immunol. 214:95-131(1996).
RN   [42]
RP   REVIEW.
RX   PubMed=9878383; DOI=10.1006/jmbi.1998.2354;
RA   Turner B.G., Summers M.F.;
RT   "Structural biology of HIV.";
RL   J. Mol. Biol. 285:1-32(1999).
RN   [43]
RP   REVIEW.
RX   PubMed=11700285; DOI=10.1146/annurev.genet.35.102401.090551;
RA   Negroni M., Buc H.;
RT   "Mechanisms of retroviral recombination.";
RL   Annu. Rev. Genet. 35:275-302(2001).
RN   [44]
RP   REVIEW.
RX   PubMed=11983066; DOI=10.1186/gb-2002-3-4-reviews3006;
RA   Dunn B.M., Goodenow M.M., Gustchina A., Wlodawer A.;
RT   "Retroviral proteases.";
RL   Genome Biol. 3:REVIEWS3006.1-REVIEWS3006.7(2002).
RN   [45]
RP   REVIEW.
RX   PubMed=12873766; DOI=10.1016/S0005-2736(03)00163-9;
RA   Scarlata S., Carter C.;
RT   "Role of HIV-1 Gag domains in viral assembly.";
RL   Biochim. Biophys. Acta 1614:62-72(2003).
RN   [46]
RP   REVIEW.
RX   PubMed=15353349; DOI=10.2741/1472;
RA   Turlure F., Devroe E., Silver P.A., Engelman A.;
RT   "Human cell proteins and human immunodeficiency virus DNA
RT   integration.";
RL   Front. Biosci. 9:3187-3208(2004).
RN   [47]
RP   REVIEW.
RX   PubMed=16815734; DOI=10.1016/j.mib.2006.06.011;
RA   Sokolskaja E., Luban J.;
RT   "Cyclophilin, TRIM5, and innate immunity to HIV-1.";
RL   Curr. Opin. Microbiol. 9:404-408(2006).
RN   [48]
RP   REVIEW.
RX   PubMed=21762797; DOI=10.1016/j.jmb.2011.04.015;
RA   Chukkapalli V., Ono A.;
RT   "Molecular determinants that regulate plasma membrane association of
RT   HIV-1 Gag.";
RL   J. Mol. Biol. 410:512-524(2011).
RN   [49]
RP   REVIEW.
RX   PubMed=24907482; DOI=10.1016/j.virusres.2014.05.011;
RA   Darlix J.L., de Rocquigny H., Mauffret O., Mely Y.;
RT   "Retrospective on the all-in-one retroviral nucleocapsid protein.";
RL   Virus Res. 193:2-15(2014).
RN   [50]
RP   REVIEW.
RX   PubMed=24933691; DOI=10.1016/j.tim.2014.04.012;
RA   Tedbury P.R., Freed E.O.;
RT   "The role of matrix in HIV-1 envelope glycoprotein incorporation.";
RL   Trends Microbiol. 22:372-378(2014).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 489-587.
RX   PubMed=2682266; DOI=10.1038/342299a0;
RA   Lapatto R., Blundell T., Hemmings A., Overington J., Wilderspin A.,
RA   Wood S., Merson J.R., Whittle P.J., Danley D.E., Geoghegan K.F.,
RA   Hawrylik S.J., Lee S.E., Scheld K.G., Hobart P.M.;
RT   "X-ray analysis of HIV-1 proteinase at 2.7-A resolution confirms
RT   structural homology among retroviral enzymes.";
RL   Nature 342:299-302(1989).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 489-587 IN COMPLEX WITH THE
RP   INHIBITOR RO 32-8959.
RX   PubMed=1956054; DOI=10.1021/jm00115a028;
RA   Krohn A., Redshaw S., Ritchie J.C., Graves B.J., Hatada M.H.;
RT   "Novel binding mode of highly potent HIV-proteinase inhibitors
RT   incorporating the (R)-hydroxyethylamine isostere.";
RL   J. Med. Chem. 34:3340-3342(1991).
RN   [53]
RP   STRUCTURE BY NMR OF 390-406.
RX   PubMed=1959614; DOI=10.1016/0014-5793(91)80825-N;
RA   Omichinski J.G., Clore G.M., Sakaguchi K., Appella E.,
RA   Gronenborn A.M.;
RT   "Structural characterization of a 39-residue synthetic peptide
RT   containing the two zinc binding domains from the HIV-1 p7 nucleocapsid
RT   protein by CD and NMR spectroscopy.";
RL   FEBS Lett. 292:25-30(1991).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 489-587 IN COMPLEX WITH A
RP   DIHYDROXYETHYLENE-CONTAINING INHIBITOR.
RX   PubMed=1304383; DOI=10.1002/pro.5560010811;
RA   Thanki N., Rao J.K., Foundling S.I., Howe W.J., Moon J.B., Hui J.O.,
RA   Tomasselli A.G., Heinrikson R.L., Thaisrivongs S., Wlodawer A.;
RT   "Crystal structure of a complex of HIV-1 protease with a
RT   dihydroxyethylene-containing inhibitor: comparisons with molecular
RT   modeling.";
RL   Protein Sci. 1:1061-1072(1992).
RN   [55]
RP   STRUCTURE BY NMR OF 390-430.
RX   PubMed=8289249;
RA   Morellet N., de Rocquigny H., Mely Y., Jullian N., Demene H.,
RA   Ottmann M., Gerard D., Darlix J.L., Fournie-Zaluski M.-C.,
RA   Roques B.P.;
RT   "Conformational behaviour of the active and inactive forms of the
RT   nucleocapsid NCp7 of HIV-1 studied by 1H NMR.";
RL   J. Mol. Biol. 235:287-301(1994).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 489-587 IN COMPLEX WITH THE
RP   INHIBITOR XK263.
RX   PubMed=8278812; DOI=10.1126/science.8278812;
RA   Lam P.Y.S., Jadhav P.K., Eyermann C.J., Hodge C.N., Ru Y.,
RA   Bacheler L.T., Meek J.L., Otto M.J., Rayner M.M., Wong Y.N.,
RA   Chang C.-H., Weber P.C., Jackson D.A., Sharpe T.R.,
RA   Erickson-Viitanen S.;
RT   "Rational design of potent, bioavailable, nonpeptide cyclic ureas as
RT   HIV protease inhibitors.";
RL   Science 263:380-384(1994).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 588-1147.
RX   PubMed=7523679; DOI=10.1006/jmbi.1994.1604;
RA   Stammers D.K., Somers D.O., Ross C.K., Kirby I., Ray P.H.,
RA   Wilson J.E., Norman M., Ren J.S., Esnouf R.M., Garman E.F.,
RA   Jones E.Y., Stuart D.I.;
RT   "Crystals of HIV-1 reverse transcriptase diffracting to 2.2 A
RT   resolution.";
RL   J. Mol. Biol. 242:586-588(1994).
RN   [58]
RP   STRUCTURE BY NMR OF 1-132.
RX   PubMed=8654825;
RA   Matthews S., Barlow P., Clark N., Kingsman S., Kingsman A.,
RA   Campbell I.;
RT   "Refined solution structure of p17, the HIV matrix protein.";
RL   Biochem. Soc. Trans. 23:725-729(1995).
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 588-1027.
RX   PubMed=8535785; DOI=10.1016/S0969-2126(01)00226-X;
RA   Ren J.S., Esnouf R.M., Hopkins A.L., Ross C.K., Jones E.Y.,
RA   Stammers D.K., Stuart D.I.;
RT   "The structure of HIV-1 reverse transcriptase complexed with 9-chloro-
RT   TIBO: lessons for inhibitor design.";
RL   Structure 3:915-926(1995).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 588-1147.
RX   PubMed=7540935; DOI=10.1038/nsb0495-303;
RA   Esnouf R.M., Ren J.S., Ross C.K., Jones E.Y., Stammers D.K.,
RA   Stuart D.I.;
RT   "Mechanism of inhibition of HIV-1 reverse transcriptase by non-
RT   nucleoside inhibitors.";
RL   Nat. Struct. Biol. 2:303-308(1995).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 588-1027.
RX   PubMed=8648598; DOI=10.1021/jm960056x;
RA   Hopkins A.L., Ren J.S., Esnouf R.M., Willcox B.E., Jones E.Y.,
RA   Ross C.K., Miyasaka T., Walker R.T., Tanaka H., Stammers D.K.,
RA   Stuart D.I.;
RT   "Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT
RT   series reveal conformational changes relevant to the design of potent
RT   non-nucleoside inhibitors.";
RL   J. Med. Chem. 39:1589-1600(1996).
RN   [62]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 489-587 IN COMPLEX WITH
RP   COMPLEX WITH DMP450.
RX   PubMed=8807858; DOI=10.1016/S1074-5521(96)90110-6;
RA   Hodge C.N., Aldrich P.E., Bacheler L.T., Chang C.-H., Eyermann C.J.,
RA   Garber S.S., Grubb M., Jackson D.A., Jadhav P.K., Korant B.D.,
RA   Lam P.Y.S., Maurin M.B., Meek J.L., Otto M.J., Rayner M.M., Reid C.,
RA   Sharpe T.R., Shum L., Winslow D.L., Erickson-Viitanen S.;
RT   "Improved cyclic urea inhibitors of the HIV-1 protease: synthesis,
RT   potency, resistance profile, human pharmacokinetics and X-ray crystal
RT   structure of DMP 450.";
RL   Chem. Biol. 3:301-314(1996).
RN   [63]
RP   STRUCTURE BY NMR OF 489-587 IN COMPLEX WITH THE INHIBITOR DMP323.
RX   PubMed=8868486; DOI=10.1002/pro.5560050311;
RA   Yamazaki T., Hinck A.P., Wang Y.X., Nicholson L.K., Torchia D.A.,
RA   Wingfield P., Stahl S.J., Kaufman J.D., Chang C.-H., Domaille P.J.,
RA   Lam P.Y.S.;
RT   "Three-dimensional solution structure of the HIV-1 protease complexed
RT   with DMP323, a novel cyclic urea-type inhibitor, determined by nuclear
RT   magnetic resonance spectroscopy.";
RL   Protein Sci. 5:495-506(1996).
RN   [64]
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 588-1130.
RX   PubMed=9108091; DOI=10.1073/pnas.94.8.3984;
RA   Esnouf R.M., Ren J.S., Hopkins A.L., Ross C.K., Jones E.Y.,
RA   Stammers D.K., Stuart D.I.;
RT   "Unique features in the structure of the complex between HIV-1 reverse
RT   transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain
RT   resistance mutations for this nonnucleoside inhibitor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:3984-3989(1997).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 489-587.
RX   PubMed=9003516; DOI=10.1021/jm960586t;
RA   Jadhav P.K., Ala P.J., Woerner F.J., Chang C.-H., Garber S.S.,
RA   Anton E.D., Bacheler L.T.;
RT   "Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar
RT   potency against both wild type and protease inhibitor resistant
RT   mutants of HIV.";
RL   J. Med. Chem. 40:181-191(1997).
RN   [66]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 489-587 IN COMPLEX WITH THE
RP   INHIBITOR LP-130.
RX   PubMed=9827997; DOI=10.1002/pro.5560071108;
RA   Kervinen J., Lubkowski J., Zdanov A., Bhatt D., Dunn B.M., Hui K.Y.,
RA   Powell D.J., Kay J., Wlodawer A., Gustchina A.;
RT   "Toward a universal inhibitor of retroviral proteases: comparative
RT   analysis of the interactions of LP-130 complexed with proteases from
RT   HIV-1, FIV, and EIAV.";
RL   Protein Sci. 7:2314-2323(1998).
RN   [67]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 489-587.
RX   PubMed=9554878; DOI=10.1021/jm970524i;
RA   Jadhav P.K., Woerner F.J., Lam P.Y., Hodge C.N., Eyermann C.J.,
RA   Man H.W., Daneker W.F., Bacheler L.T., Rayner M.M., Meek J.L.,
RA   Erickson-Viitanen S., Jackson D.A., Calabrese J.C., Schadt M.C.,
RA   Chang C.-H.;
RT   "Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors:
RT   synthesis, structure-activity relationships, and X-ray crystal
RT   structure studies.";
RL   J. Med. Chem. 41:1446-1455(1998).
RN   [68]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 489-587.
RX   PubMed=9790666; DOI=10.1021/bi980386e;
RA   Ala P.J., Huston E.E., Klabe R.M., Jadhav P.K., Lam P.Y.S.,
RA   Chang C.-H.;
RT   "Counteracting HIV-1 protease drug resistance: structural analysis of
RT   mutant proteases complexed with XV638 and SD146, cyclic urea amides
RT   with broad specificities.";
RL   Biochemistry 37:15042-15049(1998).
RN   [69]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 489-587.
RX   PubMed=9575185; DOI=10.1074/jbc.273.20.12325;
RA   Ala P.J., DeLoskey R.J., Huston E.E., Jadhav P.K., Lam P.Y.S.,
RA   Eyermann C.J., Hodge C.N., Schadt M.C., Lewandowski F.A., Weber P.C.,
RA   McCabe D.D., Duke J.L., Chang C.-H.;
RT   "Molecular recognition of cyclic urea HIV-1 protease inhibitors.";
RL   J. Biol. Chem. 273:12325-12331(1998).
RN   [70]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 490-587 IN COMPLEX WITH A
RP   TRIPEPTIDE INHIBITOR.
RX   PubMed=9485357; DOI=10.1021/bi972059x;
RA   Louis J.M., Dyda F., Nashed N.T., Kimmel A.R., Davies D.R.;
RT   "Hydrophilic peptides derived from the transframe region of Gag-Pol
RT   inhibit the HIV-1 protease.";
RL   Biochemistry 37:2105-2110(1998).
RN   [71]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 588-1130.
RX   PubMed=9689112; DOI=10.1073/pnas.95.16.9518;
RA   Ren J.S., Esnouf R.M., Hopkins A.L., Jones E.Y., Kirby I., Keeling J.,
RA   Ross C.K., Larder B.A., Stuart D.I., Stammers D.K.;
RT   "3'-azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse
RT   transcriptase can induce long range conformational changes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:9518-9523(1998).
RN   [72]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 588-1147 IN COMPLEX WITH
RP   CARBOXANILIDE DERIVATIVES.
RX   PubMed=9772165; DOI=10.1021/bi981309m;
RA   Ren J.S., Esnouf R.M., Hopkins A.L., Warren J., Balzarini J.,
RA   Stuart D.I., Stammers D.K.;
RT   "Crystal structures of HIV-1 reverse transcriptase in complex with
RT   carboxanilide derivatives.";
RL   Biochemistry 37:14394-14403(1998).
RN   [73]
RP   X-RAY CRYSTALLOGRAPHY (1.88 ANGSTROMS) OF 501-599.
RX   PubMed=10429209; DOI=10.1046/j.1432-1327.1999.00514.x;
RA   Mahalingam B., Louis J.M., Reed C.C., Adomat J.M., Krouse J.,
RA   Wang Y.-F., Harrison R.W., Weber I.T.;
RT   "Structural and kinetic analysis of drug resistant mutants of HIV-1
RT   protease.";
RL   Eur. J. Biochem. 263:238-245(1999).
RN   [74]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1199-1435.
RX   PubMed=10890912; DOI=10.1073/pnas.150220297;
RA   Chen J.C., Krucinski J., Miercke L.J., Finer-Moore J.S., Tang A.H.,
RA   Leavitt A.D., Stroud R.M.;
RT   "Crystal structure of the HIV-1 integrase catalytic core and C-
RT   terminal domains: a model for viral DNA binding.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:8233-8238(2000).
RN   [75]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 489-587.
RX   PubMed=11170214;
RX   DOI=10.1002/1097-0134(20010401)43:1<57::AID-PROT1017>3.0.CO;2-D;
RA   Pillai B., Kannan K.K., Hosur M.V.;
RT   "1.9 A X-ray study shows closed flap conformation in crystals of
RT   tethered HIV-1 PR.";
RL   Proteins 43:57-64(2001).
RN   [76]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 588-1147 IN COMPLEX WITH
RP   INHIBITORS.
RX   PubMed=11575933; DOI=10.1006/jmbi.2001.4988;
RA   Ren J.S., Nichols C.E., Bird L.E., Chamberlain P.P., Weaver K.L.,
RA   Short S.A., Stuart D.I., Stammers D.K.;
RT   "Structural mechanisms of drug resistance for mutations at codons 181
RT   and 188 in HIV-1 reverse transcriptase and the improved resilience of
RT   second generation non-nucleoside inhibitors.";
RL   J. Mol. Biol. 312:795-805(2001).
RN   [77]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 489-587.
RX   PubMed=12051725; DOI=10.1016/S0006-291X(02)00482-5;
RA   Kumar M., Kannan K.K., Hosur M.V., Bhavesh N.S., Chatterjee A.,
RA   Mittal R., Hosur R.V.;
RT   "Effects of remote mutation on the autolysis of HIV-1 PR: X-ray and
RT   NMR investigations.";
RL   Biochem. Biophys. Res. Commun. 294:395-401(2002).
RN   [78]
RP   STRUCTURE BY NMR OF 1014-1147.
RX   PubMed=12534276; DOI=10.1021/bi0204894;
RA   Pari K., Mueller G.A., DeRose E.F., Kirby T.W., London R.E.;
RT   "Solution structure of the RNase H domain of the HIV-1 reverse
RT   transcriptase in the presence of magnesium.";
RL   Biochemistry 42:639-650(2003).
RN   [79]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 588-1147 IN COMPLEX WITH
RP   INHIBITORS.
RX   PubMed=15095972; DOI=10.1016/j.jmb.2003.12.055;
RA   Ren J.S., Nichols C.E., Chamberlain P.P., Weaver K.L., Short S.A.,
RA   Stammers D.K.;
RT   "Crystal structures of HIV-1 reverse transcriptases mutated at codons
RT   100, 106 and 108 and mechanisms of resistance to non-nucleoside
RT   inhibitors.";
RL   J. Mol. Biol. 336:569-578(2004).
RN   [80]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 588-1147 IN COMPLEX WITH
RP   INHIBITORS.
RX   PubMed=15537347; DOI=10.1021/jm040072r;
RA   Freeman G.A., Andrews C.W. III, Hopkins A.L., Lowell G.S.,
RA   Schaller L.T., Cowan J.R., Gonzales S.S., Koszalka G.W., Hazen R.J.,
RA   Boone L.R., Ferris R.G., Creech K.L., Roberts G.B., Short S.A.,
RA   Weaver K.L., Reynolds D.J., Milton J., Ren J.S., Stuart D.I.,
RA   Stammers D.K., Chan J.H.;
RT   "Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase
RT   with improved drug resistance properties. 2.";
RL   J. Med. Chem. 47:5923-5936(2004).
CC   -!- FUNCTION: Gag-Pol polyprotein: Mediates, with Gag polyrotein, the
CC       essential events in virion assembly, including binding the plasma
CC       membrane, making the protein-protein interactions necessary to
CC       create spherical particles, recruiting the viral Env proteins, and
CC       packaging the genomic RNA via direct interactions with the RNA
CC       packaging sequence (Psi). Gag-Pol polyprotein may regulate its own
CC       translation, by the binding genomic RNA in the 5'-UTR. At low
CC       concentration, the polyprotein would promote translation, whereas
CC       at high concentration, the polyprotein would encapsidate genomic
CC       RNA and then shutt off translation.
CC   -!- FUNCTION: Matrix protein p17: Targets the polyprotein to the
CC       plasma membrane via a multipartite membrane-binding signal, that
CC       includes its myristoylated N-terminus (By similarity). Matrix
CC       protein is part of the pre-integration complex. Implicated in the
CC       release from host cell mediated by Vpu. Binds to RNA (By
CC       similarity). {ECO:0000250|UniProtKB:P12497}.
CC   -!- FUNCTION: Capsid protein p24: Forms the conical core that
CC       encapsulates the genomic RNA-nucleocapsid complex in the virion
CC       (PubMed:8648689). Most core are conical, with only 7% tubular. The
CC       core is constituted by capsid protein hexamer subunits. The core
CC       is disassembled soon after virion entry (PubMed:12660176). Host
CC       restriction factors such as monkey TRIM5-alpha or TRIMCyp bind
CC       retroviral capsids and cause premature capsid disassembly, leading
CC       to blocks in reverse transcription. Capsid restriction by TRIM5 is
CC       one of the factors which restricts HIV-1 to the human species
CC       (PubMed:23785198). Host PIN1 apparently facilitates the virion
CC       uncoating (By similarity). On the other hand, interactions with
CC       PDZD8 or CYPA stabilize the capsid (PubMed:24554657).
CC       {ECO:0000250|UniProtKB:P12497, ECO:0000269|PubMed:12660176,
CC       ECO:0000269|PubMed:23785198, ECO:0000269|PubMed:24554657,
CC       ECO:0000269|PubMed:8648689}.
CC   -!- FUNCTION: Nucleocapsid protein p7: Encapsulates and protects viral
CC       dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its
CC       zinc fingers. Acts as a nucleic acid chaperone which is involved
CC       in rearangement of nucleic acid secondary structure during gRNA
CC       retrotranscription. Also facilitates template switch leading to
CC       recombination. As part of the polyprotein, participates to gRNA
CC       dimerization, packaging, tRNA incorporation and virion assembly.
CC       {ECO:0000269|PubMed:11044125, ECO:0000269|PubMed:17070549,
CC       ECO:0000269|PubMed:18343475, ECO:0000269|PubMed:20828778,
CC       ECO:0000269|PubMed:9931246}.
CC   -!- FUNCTION: Protease: Aspartyl protease that mediates proteolytic
CC       cleavages of Gag and Gag-Pol polyproteins during or shortly after
CC       the release of the virion from the plasma membrane
CC       (PubMed:9573231) (PubMed:11932404). Cleavages take place as an
CC       ordered, step-wise cascade to yield mature proteins
CC       (PubMed:9573231) (PubMed:11932404). This process is called
CC       maturation (PubMed:9573231) (PubMed:11932404). Displays maximal
CC       activity during the budding process just prior to particle release
CC       from the cell (PubMed:9573231) (PubMed:11932404). Also cleaves Nef
CC       and Vif, probably concomitantly with viral structural proteins on
CC       maturation of virus particles (PubMed:7835426). Hydrolyzes host
CC       EIF4GI and PABP1 in order to shut off the capped cellular mRNA
CC       translation. The resulting inhibition of cellular protein
CC       synthesis serves to ensure maximal viral gene expression and to
CC       evade host immune response (PubMed:12660176) (PubMed:19914170).
CC       {ECO:0000250, ECO:0000255|PROSITE-ProRule:PRU00275,
CC       ECO:0000269|PubMed:12505164, ECO:0000269|PubMed:19956697,
CC       ECO:0000269|PubMed:7835426}.
CC   -!- FUNCTION: Reverse transcriptase/ribonuclease H: Multifunctional
CC       enzyme that converts the viral RNA genome into dsDNA in the
CC       cytoplasm, shortly after virus entry into the cell. This enzyme
CC       displays a DNA polymerase activity that can copy either DNA or RNA
CC       templates, and a ribonuclease H (RNase H) activity that cleaves
CC       the RNA strand of RNA-DNA heteroduplexes in a partially processive
CC       3' to 5' endonucleasic mode. Conversion of viral genomic RNA into
CC       dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-
CC       binding site (PBS) situated at the 5'-end of the viral RNA. RT
CC       uses the 3' end of the tRNA primer to perform a short round of
CC       RNA-dependent minus-strand DNA synthesis. The reading proceeds
CC       through the U5 region and ends after the repeated (R) region which
CC       is present at both ends of viral RNA. The portion of the RNA-DNA
CC       heteroduplex is digested by the RNase H, resulting in a ssDNA
CC       product attached to the tRNA primer. This ssDNA/tRNA hybridizes
CC       with the identical R region situated at the 3' end of viral RNA.
CC       This template exchange, known as minus-strand DNA strong stop
CC       transfer, can be either intra- or intermolecular. RT uses the 3'
CC       end of this newly synthesized short ssDNA to perform the RNA-
CC       dependent minus-strand DNA synthesis of the whole template. RNase
CC       H digests the RNA template except for two polypurine tracts (PPTs)
CC       situated at the 5'-end and near the center of the genome. It is
CC       not clear if both polymerase and RNase H activities are
CC       simultaneous. RNase H probably can proceed both in a polymerase-
CC       dependent (RNA cut into small fragments by the same RT performing
CC       DNA synthesis) and a polymerase-independent mode (cleavage of
CC       remaining RNA fragments by free RTs). Secondly, RT performs DNA-
CC       directed plus-strand DNA synthesis using the PPTs that have not
CC       been removed by RNase H as primers. PPTs and tRNA primers are then
CC       removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to
CC       form a circular dsDNA intermediate. Strand displacement synthesis
CC       by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA
CC       copy of the viral genome that includes long terminal repeats
CC       (LTRs) at both ends. {ECO:0000269|PubMed:16221683}.
CC   -!- FUNCTION: Integrase: Catalyzes viral DNA integration into the host
CC       chromosome, by performing a series of DNA cutting and joining
CC       reactions. This enzyme activity takes place after virion entry
CC       into a cell and reverse transcription of the RNA genome in dsDNA.
CC       The first step in the integration process is 3' processing. This
CC       step requires a complex comprising the viral genome, matrix
CC       protein, Vpr and integrase. This complex is called the pre-
CC       integration complex (PIC). The integrase protein removes 2
CC       nucleotides from each 3' end of the viral DNA, leaving recessed CA
CC       OH's at the 3' ends. In the second step, the PIC enters cell
CC       nucleus. This process is mediated through integrase and Vpr
CC       proteins, and allows the virus to infect a non dividing cell. This
CC       ability to enter the nucleus is specific of lentiviruses, other
CC       retroviruses cannot and rely on cell division to access cell
CC       chromosomes. In the third step, termed strand transfer, the
CC       integrase protein joins the previously processed 3' ends to the 5'
CC       ends of strands of target cellular DNA at the site of integration.
CC       The 5'-ends are produced by integrase-catalyzed staggered cuts, 5
CC       bp apart. A Y-shaped, gapped, recombination intermediate results,
CC       with the 5'-ends of the viral DNA strands and the 3' ends of
CC       target DNA strands remaining unjoined, flanking a gap of 5 bp. The
CC       last step is viral DNA integration into host chromosome. This
CC       involves host DNA repair synthesis in which the 5 bp gaps between
CC       the unjoined strands are filled in and then ligated. Since this
CC       process occurs at both cuts flanking the HIV genome, a 5 bp
CC       duplication of host DNA is produced at the ends of HIV-1
CC       integration. Alternatively, Integrase may catalyze the excision of
CC       viral DNA just after strand transfer, this is termed
CC       disintegration. {ECO:0000269|PubMed:20554775}.
CC   -!- CATALYTIC ACTIVITY: Specific for a P1 residue that is hydrophobic,
CC       and P1' variable, but often Pro. {ECO:0000255|PROSITE-
CC       ProRule:PRU00275}.
CC   -!- CATALYTIC ACTIVITY: Endohydrolysis of RNA in RNA/DNA hybrids.
CC       Three different cleavage modes: 1. sequence-specific internal
CC       cleavage of RNA. Human immunodeficiency virus type 1 and Moloney
CC       murine leukemia virus enzymes prefer to cleave the RNA strand one
CC       nucleotide away from the RNA-DNA junction. 2. RNA 5'-end directed
CC       cleavage 13-19 nucleotides from the RNA end. 3. DNA 3'-end
CC       directed cleavage 15-20 nucleotides away from the primer terminus.
CC   -!- CATALYTIC ACTIVITY: 3'-end directed exonucleolytic cleavage of
CC       viral RNA-DNA hybrid.
CC   -!- CATALYTIC ACTIVITY: Deoxynucleoside triphosphate + DNA(n) =
CC       diphosphate + DNA(n+1). {ECO:0000255|PROSITE-ProRule:PRU00405}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Binds 2 magnesium ions for reverse transcriptase polymerase
CC       activity. {ECO:0000250};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Binds 2 magnesium ions for ribonuclease H (RNase H) activity.
CC       Substrate-binding is a precondition for magnesium binding.
CC       {ECO:0000250};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Magnesium ions are required for integrase activity. Binds at
CC       least 1, maybe 2 magnesium ions. {ECO:0000250};
CC   -!- ENZYME REGULATION: Protease: The viral protease is inhibited by
CC       many synthetic protease inhibitors (PIs), such as amprenavir,
CC       atazanavir, indinavir, loprinavir, nelfinavir, ritonavir and
CC       saquinavir. Use of protease inhibitors in tritherapy regimens
CC       permit more ambitious therapeutic strategies. Reverse
CC       transcriptase/ribonuclease H: RT can be inhibited either by
CC       nucleoside RT inhibitors (NRTIs) or by non nucleoside RT
CC       inhibitors (NNRTIs). NRTIs act as chain terminators, whereas
CC       NNRTIs inhibit DNA polymerization by binding a small hydrophobic
CC       pocket near the RT active site and inducing an allosteric change
CC       in this region. Classical NRTIs are abacavir, adefovir (PMEA),
CC       didanosine (ddI), lamivudine (3TC), stavudine (d4T), tenofovir
CC       (PMPA), zalcitabine (ddC), and zidovudine (AZT). Classical NNRTIs
CC       are atevirdine (BHAP U-87201E), delavirdine, efavirenz (DMP-266),
CC       emivirine (I-EBU), and nevirapine (BI-RG-587). The tritherapies
CC       used as a basic effective treatment of AIDS associate two NRTIs
CC       and one NNRTI.
CC   -!- SUBUNIT: Matrix protein p17: Homotrimer; further assembles as
CC       hexamers of trimers (PubMed:19327811). Matrix protein p17:
CC       Interacts with gp41 (via C-terminus) (By similarity). Matrix
CC       protein p17: interacts with host CALM1; this interaction induces a
CC       conformational change in the Matrix protein, triggering exposure
CC       of the myristate group (PubMed:24500712). Matrix protein p17:
CC       interacts with host AP3D1; this interaction allows the polyprotein
CC       trafficking to multivesicular bodies during virus assembly (By
CC       similarity). Matrix protein p17: Part of the pre-integration
CC       complex (PIC) which is composed of viral genome, matrix protein,
CC       Vpr and integrase (By similarity). Capsid protein p24: Homodimer;
CC       the homodimer further multimerizes as homohexamers or
CC       homopentamers (PubMed:19914170). Capsid protein p24: Interacts
CC       with human PPIA/CYPA (PubMed:9223641); this interaction stabilizes
CC       the capsid. Capsid protein p24: Interacts with human NUP153 (By
CC       similarity). Capsid protein p24: Interacts with host PDZD8; this
CC       interaction stabilizes the capsid (PubMed:20573829). Capsid
CC       protein p24: Interacts with monkey TRIM5; this interaction
CC       destabilizes the capsid (PubMed:23785198). Protease: Homodimer,
CC       whose active site consists of two apposed aspartic acid residues
CC       (PubMed:2162350) (PubMed:24132393). Reverse
CC       transcriptase/ribonuclease H: Heterodimer of p66 RT and p51 RT (RT
CC       p66/p51). Heterodimerization of RT is essential for DNA polymerase
CC       activity. Despite the sequence identities, p66 RT and p51 RT have
CC       distinct folding. Integrase: Homodimer; possibly can form
CC       homotetramer. Integrase: Part of the pre-integration complex (PIC)
CC       which is composed of viral genome, matrix protein, Vpr and
CC       integrase. Integrase: Interacts with human SMARCB1/INI1 and human
CC       PSIP1/LEDGF isoform 1 (PubMed:7801128). Integrase: Interacts with
CC       human KPNA3; this interaction might play a role in nuclear import
CC       of the pre-integration complex (PubMed:19914170). Integrase:
CC       Interacts with human NUP153; this interaction might play a role in
CC       nuclear import of the pre-integration complex (By similarity).
CC       {ECO:0000250|UniProtKB:P12497, ECO:0000269|PubMed:19327811,
CC       ECO:0000269|PubMed:19914170, ECO:0000269|PubMed:20573829,
CC       ECO:0000269|PubMed:2162350, ECO:0000269|PubMed:23785198,
CC       ECO:0000269|PubMed:24132393, ECO:0000269|PubMed:24500712,
CC       ECO:0000269|PubMed:7801128, ECO:0000269|PubMed:8513493,
CC       ECO:0000269|PubMed:9223641}.
CC   -!- INTERACTION:
CC       Self; NbExp=29; IntAct=EBI-3989067, EBI-3989067;
CC       O00629:KPNA4 (xeno); NbExp=4; IntAct=EBI-9872653, EBI-396343;
CC       O75475:PSIP1 (xeno); NbExp=21; IntAct=EBI-3989067, EBI-1801773;
CC       O75475-1:PSIP1 (xeno); NbExp=2; IntAct=EBI-9872653, EBI-5279836;
CC       P69718:rev (xeno); NbExp=8; IntAct=EBI-3989067, EBI-8540156;
CC       Q12824:SMARCB1 (xeno); NbExp=3; IntAct=EBI-9872653, EBI-358419;
CC       Q9Y5L0:TNPO3 (xeno); NbExp=6; IntAct=EBI-9872653, EBI-1042571;
CC   -!- SUBCELLULAR LOCATION: Gag-Pol polyprotein: Host cell membrane;
CC       Lipid-anchor {ECO:0000250|UniProtKB:P12493}. Host endosome, host
CC       multivesicular body {ECO:0000250|UniProtKB:P12493}. Note=These
CC       locations are linked to virus assembly sites. The main location is
CC       the cell membrane, but under some circumstances, late endosomal
CC       compartments can serve as productive sites for virion assembly.
CC       {ECO:0000250|UniProtKB:P12493}.
CC   -!- SUBCELLULAR LOCATION: Matrix protein p17: Virion membrane; Lipid-
CC       anchor {ECO:0000305}. Host nucleus {ECO:0000250}. Host cytoplasm
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Capsid protein p24: Virion {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Nucleocapsid protein p7: Virion
CC       {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Reverse transcriptase/ribonuclease H: Virion
CC       {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Integrase: Virion {ECO:0000305}. Host
CC       nucleus {ECO:0000305}. Host cytoplasm {ECO:0000305}. Note=Nuclear
CC       at initial phase, cytoplasmic at assembly. {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Ribosomal frameshifting; Named isoforms=2;
CC         Comment=Translation results in the formation of the Gag
CC         polyprotein most of the time. Ribosomal frameshifting at the
CC         gag-pol genes boundary occurs at low frequency and produces the
CC         Gag-Pol polyprotein. This strategy of translation probably
CC         allows the virus to modulate the quantity of each viral protein.
CC         Maintenance of a correct Gag to Gag-Pol ratio is essential for
CC         RNA dimerization and viral infectivity.;
CC       Name=Gag-Pol polyprotein;
CC         IsoId=P04585-1; Sequence=Displayed;
CC         Note=Produced by -1 ribosomal frameshifting.;
CC       Name=Gag polyprotein;
CC         IsoId=P04591-1; Sequence=External;
CC         Note=Produced by conventional translation.;
CC   -!- DOMAIN: Reverse transcriptase/ribonuclease H: RT is structured in
CC       five subdomains: finger, palm, thumb, connection and RNase H.
CC       Within the palm subdomain, the 'primer grip' region is thought to
CC       be involved in the positioning of the primer terminus for
CC       accommodating the incoming nucleotide. The RNase H domain
CC       stabilizes the association of RT with primer-template (By
CC       similarity). {ECO:0000250}.
CC   -!- DOMAIN: Reverse transcriptase/ribonuclease H: The tryptophan
CC       repeat motif is involved in RT p66/p51 dimerization.
CC   -!- DOMAIN: Integrase: The core domain contains the D-x(n)-D-x(35)-E
CC       motif, named for the phylogenetically conserved glutamic acid and
CC       aspartic acid residues and the invariant 35 amino acid spacing
CC       between the second and third acidic residues. Each acidic residue
CC       of the D,D(35)E motif is independently essential for the 3'-
CC       processing and strand transfer activities of purified integrase
CC       protein.
CC   -!- PTM: Gag-Pol polyprotein: Specific enzymatic cleavages by the
CC       viral protease yield mature proteins. The protease is released by
CC       autocatalytic cleavage. The polyprotein is cleaved during and
CC       after budding, this process is termed maturation. Proteolytic
CC       cleavage of p66 RT removes the RNase H domain to yield the p51 RT
CC       subunit. Nucleocapsid protein p7 might be further cleaved after
CC       virus entry. {ECO:0000255|PROSITE-ProRule:PRU00405,
CC       ECO:0000269|PubMed:10494040, ECO:0000269|PubMed:12477841,
CC       ECO:0000269|PubMed:15065874}.
CC   -!- PTM: Matrix protein p17: Tyrosine phosphorylated presumably in the
CC       virion by a host kinase. Phosphorylation is apparently not a major
CC       regulator of membrane association (PubMed:17656588).
CC       {ECO:0000269|PubMed:17656588}.
CC   -!- PTM: Capsid protein p24: Phosphorylated possibly by host MAPK1;
CC       this phosphorylation is necessary for Pin1-mediated virion
CC       uncoating. {ECO:0000250|UniProtKB:P12493}.
CC   -!- PTM: Nucleocapsid protein p7: Methylated by host PRMT6, impairing
CC       its function by reducing RNA annealing and the initiation of
CC       reverse transcription. {ECO:0000250|UniProtKB:P03366}.
CC   -!- MISCELLANEOUS: Reverse transcriptase/ribonuclease H: Error-prone
CC       enzyme that lacks a proof-reading function. High mutations rate is
CC       a direct consequence of this characteristic. RT also displays
CC       frequent template switching leading to high recombination rate.
CC       Recombination mostly occurs between homologous regions of the two
CC       copackaged RNA genomes. If these two RNA molecules derive from
CC       different viral strains, reverse transcription will give rise to
CC       highly recombinated proviral DNAs.
CC   -!- MISCELLANEOUS: HIV-1 lineages are divided in three main groups, M
CC       (for Major), O (for Outlier), and N (for New, or Non-M, Non-O).
CC       The vast majority of strains found worldwide belong to the group
CC       M. Group O seems to be endemic to and largely confined to Cameroon
CC       and neighboring countries in West Central Africa, where these
CC       viruses represent a small minority of HIV-1 strains. The group N
CC       is represented by a limited number of isolates from Cameroonian
CC       persons. The group M is further subdivided in 9 clades or subtypes
CC       (A to D, F to H, J and K).
CC   -!- MISCELLANEOUS: Resistance to inhibitors associated with mutations
CC       are observed both in viral protease and in reverse transcriptase.
CC       Most of the time, single mutations confer only a modest reduction
CC       in drug susceptibility. Combination of several mutations is
CC       usually required to develop a high-level drug resistance. These
CC       mutations are predominantly found in clade B viruses and not in
CC       other genotypes. They are listed in this entry which is a
CC       representative of clade B.
CC   -!- SIMILARITY: Contains 2 CCHC-type zinc fingers.
CC       {ECO:0000255|PROSITE-ProRule:PRU00047}.
CC   -!- SIMILARITY: Contains 1 integrase catalytic domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00457}.
CC   -!- SIMILARITY: Contains 1 integrase-type DNA-binding domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00506}.
CC   -!- SIMILARITY: Contains 1 integrase-type zinc finger.
CC       {ECO:0000255|PROSITE-ProRule:PRU00450}.
CC   -!- SIMILARITY: Contains 1 peptidase A2 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00275}.
CC   -!- SIMILARITY: Contains 1 reverse transcriptase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00405}.
CC   -!- SIMILARITY: Contains 1 RNase H domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00408}.
CC   -!- WEB RESOURCE: Name=HIV drug resistance mutations;
CC       URL="https://www.iasusa.org/content/hiv-drug-resistance-mutations";
CC   -!- WEB RESOURCE: Name=hivdb; Note=HIV drug resistance database;
CC       URL="http://hivdb.stanford.edu";
CC   -!- WEB RESOURCE: Name=BioAfrica HIV proteomics resource; Note=Pol
CC       entry;
CC       URL="http://www.bioafrica.net/proteomics/POLprot.html";
CC   -!- WEB RESOURCE: Name=BioAfrica HIV proteomics resource; Note=RT
CC       (p51) entry;
CC       URL="http://www.bioafrica.net/proteomics/POL-RTprot.html";
CC   -!- WEB RESOURCE: Name=BioAfrica HIV proteomics resource; Note=RNase H
CC       (p15) entry;
CC       URL="http://www.bioafrica.net/proteomics/POL-RNHprot.html";
CC   -!- WEB RESOURCE: Name=BioAfrica HIV proteomics resource; Note=PR
CC       (p15) entry;
CC       URL="http://www.bioafrica.net/proteomics/POL-PRprot.html";
CC   -!- WEB RESOURCE: Name=BioAfrica HIV proteomics resource; Note=IN
CC       (p31) entry;
CC       URL="http://www.bioafrica.net/proteomics/POL-INprot.html";
CC   -!- WEB RESOURCE: Name=BioAfrica: HIV bioinformatics in Africa;
CC       URL="http://www.bioafrica.net/index.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; K03455; AAB50259.1; ALT_SEQ; Genomic_RNA.
DR   EMBL; AF033819; AAC82598.2; ALT_SEQ; Genomic_RNA.
DR   RefSeq; NP_057849.4; NC_001802.1.
DR   PDB; 1A30; X-ray; 2.00 A; A/B=489-587.
DR   PDB; 1BV7; X-ray; 2.00 A; A/B=489-587.
DR   PDB; 1BV9; X-ray; 2.00 A; A/B=489-587.
DR   PDB; 1BVE; NMR; -; A/B=489-587.
DR   PDB; 1BVG; NMR; -; A/B=489-587.
DR   PDB; 1BWA; X-ray; 1.90 A; A/B=489-587.
DR   PDB; 1BWB; X-ray; 1.80 A; A/B=489-587.
DR   PDB; 1C0T; X-ray; 2.70 A; A=588-1147, B=588-1027.
DR   PDB; 1C0U; X-ray; 2.52 A; A=588-1147, B=588-1027.
DR   PDB; 1C1B; X-ray; 2.50 A; A=588-1147, B=588-1428.
DR   PDB; 1C1C; X-ray; 2.50 A; A=588-1147, B=588-1027.
DR   PDB; 1DMP; X-ray; 2.00 A; A/B=489-587.
DR   PDB; 1DTQ; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 1DTT; X-ray; 3.00 A; A=588-1147, B=588-1027.
DR   PDB; 1E6J; X-ray; 3.00 A; P=143-352.
DR   PDB; 1EP4; X-ray; 2.50 A; A=588-1147, B=588-1027.
DR   PDB; 1ESK; NMR; -; A=390-430.
DR   PDB; 1EX4; X-ray; 2.80 A; A/B=1199-1435.
DR   PDB; 1EXQ; X-ray; 1.60 A; A/B=1203-1356.
DR   PDB; 1FB7; X-ray; 2.60 A; A=489-587.
DR   PDB; 1FK9; X-ray; 2.50 A; A=588-1130, B=588-1027.
DR   PDB; 1FKO; X-ray; 2.90 A; A=588-1130, B=588-1027.
DR   PDB; 1FKP; X-ray; 2.90 A; A=588-1130, B=588-1027.
DR   PDB; 1G6L; X-ray; 1.90 A; A=484-587.
DR   PDB; 1HIV; X-ray; 2.00 A; A/B=489-587.
DR   PDB; 1HVH; X-ray; 1.80 A; A/B=489-587.
DR   PDB; 1HVR; X-ray; 1.80 A; A/B=489-587.
DR   PDB; 1HWR; X-ray; 1.80 A; A/B=489-587.
DR   PDB; 1HXB; X-ray; 2.30 A; A/B=489-587.
DR   PDB; 1JKH; X-ray; 2.50 A; A=588-1147, B=588-1027.
DR   PDB; 1JLA; X-ray; 2.50 A; A=588-1147, B=588-1027.
DR   PDB; 1JLB; X-ray; 3.00 A; A=588-1147, B=588-1027.
DR   PDB; 1JLC; X-ray; 3.00 A; A=588-1147, B=588-1027.
DR   PDB; 1JLE; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 1JLF; X-ray; 2.60 A; A=588-1147, B=588-1027.
DR   PDB; 1JLG; X-ray; 2.60 A; A=588-1147, B=588-1027.
DR   PDB; 1JLQ; X-ray; 3.00 A; A=588-1147, B=588-1027.
DR   PDB; 1KLM; X-ray; 2.65 A; A=588-1147, B=588-1027.
DR   PDB; 1LV1; X-ray; 2.10 A; A=484-587.
DR   PDB; 1LW0; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 1LW2; X-ray; 3.00 A; A=588-1147, B=588-1027.
DR   PDB; 1LWC; X-ray; 2.62 A; A=588-1147, B=588-1027.
DR   PDB; 1LWE; X-ray; 2.81 A; A=588-1147, B=588-1027.
DR   PDB; 1LWF; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 1NCP; NMR; -; N=390-406.
DR   PDB; 1O1W; NMR; -; A=1014-1147.
DR   PDB; 1ODW; X-ray; 2.10 A; A/B=489-587.
DR   PDB; 1ODY; X-ray; 2.00 A; A/B=489-587.
DR   PDB; 1QBR; X-ray; 1.80 A; A/B=489-587.
DR   PDB; 1QBS; X-ray; 1.80 A; A/B=489-587.
DR   PDB; 1QBT; X-ray; 2.10 A; A/B=489-587.
DR   PDB; 1QBU; X-ray; 1.80 A; A/B=489-587.
DR   PDB; 1REV; X-ray; 2.60 A; A=588-1147, B=588-1027.
DR   PDB; 1RT1; X-ray; 2.55 A; A=588-1147, B=588-1027.
DR   PDB; 1RT2; X-ray; 2.55 A; A=588-1147, B=588-1027.
DR   PDB; 1RT3; X-ray; 3.00 A; A=588-1147, B=588-1027.
DR   PDB; 1RT4; X-ray; 2.90 A; A=588-1147, B=588-1027.
DR   PDB; 1RT5; X-ray; 2.90 A; A=588-1147, B=588-1027.
DR   PDB; 1RT6; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 1RT7; X-ray; 3.00 A; A=588-1147, B=588-1027.
DR   PDB; 1RTD; X-ray; 3.20 A; B/D=588-1027.
DR   PDB; 1RTH; X-ray; 2.20 A; A=588-1147, B=588-1027.
DR   PDB; 1RTI; X-ray; 3.00 A; A=588-1147, B=588-1027.
DR   PDB; 1RTJ; X-ray; 2.35 A; A=588-1147, B=588-1027.
DR   PDB; 1S1T; X-ray; 2.40 A; A=588-1147, B=588-1027.
DR   PDB; 1S1U; X-ray; 3.00 A; A=588-1147, B=588-1027.
DR   PDB; 1S1V; X-ray; 2.60 A; A=588-1147, B=588-1027.
DR   PDB; 1S1W; X-ray; 2.70 A; A=588-1147, B=588-1027.
DR   PDB; 1S1X; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 1T05; X-ray; 3.00 A; B=588-1016.
DR   PDB; 1TAM; NMR; -; A=1-132.
DR   PDB; 1TKT; X-ray; 2.60 A; A=588-1147, B=588-1027.
DR   PDB; 1TKX; X-ray; 2.85 A; A=588-1147, B=588-1027.
DR   PDB; 1TKZ; X-ray; 2.81 A; A=588-1147, B=588-1027.
DR   PDB; 1TL1; X-ray; 2.90 A; A=588-1147, B=588-1027.
DR   PDB; 1TL3; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 1VRT; X-ray; 2.20 A; A=588-1147, B=588-1027.
DR   PDB; 1VRU; X-ray; 2.40 A; A=588-1147, B=588-1027.
DR   PDB; 2HND; X-ray; 2.50 A; A=591-1124.
DR   PDB; 2HNY; X-ray; 2.50 A; A=591-1124.
DR   PDB; 2HNZ; X-ray; 3.00 A; A=591-1124, B=594-1015.
DR   PDB; 2KOD; NMR; -; A/B=276-363.
DR   PDB; 2NPH; X-ray; 1.65 A; A/B=489-587.
DR   PDB; 2OPP; X-ray; 2.55 A; A=591-1132, B=592-1018.
DR   PDB; 2OPQ; X-ray; 2.80 A; A=591-1124, B=592-1015.
DR   PDB; 2OPR; X-ray; 2.90 A; A=589-1135, B=593-1018.
DR   PDB; 2OPS; X-ray; 2.30 A; A=589-1130, B=593-1027.
DR   PDB; 2RF2; X-ray; 2.40 A; A=588-1147, B=588-1027.
DR   PDB; 2RKI; X-ray; 2.30 A; A=588-1147, B=588-1027.
DR   PDB; 2WHH; X-ray; 1.69 A; A=489-587.
DR   PDB; 2WOM; X-ray; 3.20 A; A=588-1147, B=588-1027.
DR   PDB; 2WON; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 2YNF; X-ray; 2.36 A; A=588-1147, B=588-1015.
DR   PDB; 2YNG; X-ray; 2.12 A; A=588-1147, B=588-1015.
DR   PDB; 2YNH; X-ray; 2.90 A; A=588-1147, B=588-1015.
DR   PDB; 2YNI; X-ray; 2.49 A; A=588-1147, B=588-1015.
DR   PDB; 3AO2; X-ray; 1.80 A; A/B=1197-1359.
DR   PDB; 3C6T; X-ray; 2.70 A; A=588-1147, B=588-1027.
DR   PDB; 3C6U; X-ray; 2.70 A; A=588-1147, B=588-1027.
DR   PDB; 3DI6; X-ray; 2.65 A; A=588-1148, B=588-1027.
DR   PDB; 3DLE; X-ray; 2.50 A; A=588-1147, B=588-1027.
DR   PDB; 3DLG; X-ray; 2.20 A; A=588-1147, B=588-1027.
DR   PDB; 3DM2; X-ray; 3.10 A; A=588-1147, B=588-1027.
DR   PDB; 3DMJ; X-ray; 2.60 A; A=588-1147, B=588-1027.
DR   PDB; 3DOK; X-ray; 2.90 A; A=588-1147, B=588-1027.
DR   PDB; 3DOL; X-ray; 2.50 A; A=588-1147, B=588-1027.
DR   PDB; 3DOX; X-ray; 2.00 A; A=484-587.
DR   PDB; 3DRP; X-ray; 2.60 A; A=588-1147, B=588-1027.
DR   PDB; 3DRR; X-ray; 2.89 A; A=588-1147, B=588-1027.
DR   PDB; 3DRS; X-ray; 3.15 A; A=588-1147, B=588-1027.
DR   PDB; 3DYA; X-ray; 2.30 A; A=588-1148, B=588-1027.
DR   PDB; 3E01; X-ray; 2.95 A; A=588-1148, B=588-1027.
DR   PDB; 3FFI; X-ray; 2.60 A; A=588-1147, B=588-1027.
DR   PDB; 3I0R; X-ray; 2.98 A; A=588-1147, B=588-1027.
DR   PDB; 3I0S; X-ray; 2.70 A; A=588-1147, B=588-1027.
DR   PDB; 3KJV; X-ray; 3.10 A; A=588-1147, B=588-1027.
DR   PDB; 3KK1; X-ray; 2.70 A; A=588-1147, B=588-1027.
DR   PDB; 3KK2; X-ray; 2.90 A; A=588-1147, B=588-1027.
DR   PDB; 3KK3; X-ray; 2.90 A; A=588-1147, B=588-1027.
DR   PDB; 3KT2; X-ray; 1.65 A; A=484-587.
DR   PDB; 3KT5; X-ray; 1.80 A; A=484-587.
DR   PDB; 3LAK; X-ray; 2.30 A; A/B=588-1147.
DR   PDB; 3LAL; X-ray; 2.51 A; A/B=588-1147.
DR   PDB; 3LAM; X-ray; 2.76 A; A/B=588-1147.
DR   PDB; 3LAN; X-ray; 2.55 A; A/B=588-1147.
DR   PDB; 3LP0; X-ray; 2.79 A; A=588-1147, B=588-1027.
DR   PDB; 3LP1; X-ray; 2.23 A; A=588-1147, B=588-1027.
DR   PDB; 3LP2; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 3M8P; X-ray; 2.67 A; A=588-1148, B=588-1027.
DR   PDB; 3M8Q; X-ray; 2.70 A; A=588-1148, B=588-1027.
DR   PDB; 3MEC; X-ray; 2.30 A; A=588-1147, B=588-1027.
DR   PDB; 3MED; X-ray; 2.50 A; A=588-1147, B=588-1027.
DR   PDB; 3MEE; X-ray; 2.40 A; A=588-1147, B=588-1027.
DR   PDB; 3MEG; X-ray; 2.80 A; A=588-1147, B=588-1027.
DR   PDB; 3MIM; X-ray; 1.76 A; A/B=489-587.
DR   PDB; 3N3I; X-ray; 2.50 A; A=484-587.
DR   PDB; 3NBP; X-ray; 2.95 A; A=588-1148, B=588-1027.
DR   PDB; 3PHV; X-ray; 2.70 A; A=489-587.
DR   PDB; 3QIN; X-ray; 1.70 A; A=1014-1103, A=1142-1148.
DR   PDB; 3QIO; X-ray; 1.40 A; A=1014-1148.
DR   PDB; 3QIP; X-ray; 2.09 A; A=588-1147, B=588-1027.
DR   PDB; 3T19; X-ray; 2.60 A; A/B=588-1147.
DR   PDB; 3T1A; X-ray; 2.40 A; A/B=588-1147.
DR   PDB; 3TAM; X-ray; 2.51 A; A=590-1147, B=588-1027.
DR   PDB; 4B3O; X-ray; 3.30 A; A=588-1145, B=588-1027.
DR   PDB; 4B3P; X-ray; 4.84 A; A=588-1145, B=588-1027.
DR   PDB; 4B3Q; X-ray; 5.00 A; A=588-1145, B=588-1027.
DR   PDB; 4I7F; X-ray; 2.50 A; A=588-1147, B=588-1027.
DR   PDB; 4KSE; X-ray; 2.68 A; B=588-1017.
DR   PDB; 4KV8; X-ray; 2.30 A; A=588-1147, B=588-1027.
DR   PDB; 4NCG; X-ray; 2.58 A; A=588-1147, B=585-1027.
DR   PDB; 4Q5M; X-ray; 1.79 A; A=484-587.
DR   PDB; 4QLH; X-ray; 2.45 A; A=489-587.
DR   PDBsum; 1A30; -.
DR   PDBsum; 1BV7; -.
DR   PDBsum; 1BV9; -.
DR   PDBsum; 1BVE; -.
DR   PDBsum; 1BVG; -.
DR   PDBsum; 1BWA; -.
DR   PDBsum; 1BWB; -.
DR   PDBsum; 1C0T; -.
DR   PDBsum; 1C0U; -.
DR   PDBsum; 1C1B; -.
DR   PDBsum; 1C1C; -.
DR   PDBsum; 1DMP; -.
DR   PDBsum; 1DTQ; -.
DR   PDBsum; 1DTT; -.
DR   PDBsum; 1E6J; -.
DR   PDBsum; 1EP4; -.
DR   PDBsum; 1ESK; -.
DR   PDBsum; 1EX4; -.
DR   PDBsum; 1EXQ; -.
DR   PDBsum; 1FB7; -.
DR   PDBsum; 1FK9; -.
DR   PDBsum; 1FKO; -.
DR   PDBsum; 1FKP; -.
DR   PDBsum; 1G6L; -.
DR   PDBsum; 1HIV; -.
DR   PDBsum; 1HVH; -.
DR   PDBsum; 1HVR; -.
DR   PDBsum; 1HWR; -.
DR   PDBsum; 1HXB; -.
DR   PDBsum; 1JKH; -.
DR   PDBsum; 1JLA; -.
DR   PDBsum; 1JLB; -.
DR   PDBsum; 1JLC; -.
DR   PDBsum; 1JLE; -.
DR   PDBsum; 1JLF; -.
DR   PDBsum; 1JLG; -.
DR   PDBsum; 1JLQ; -.
DR   PDBsum; 1KLM; -.
DR   PDBsum; 1LV1; -.
DR   PDBsum; 1LW0; -.
DR   PDBsum; 1LW2; -.
DR   PDBsum; 1LWC; -.
DR   PDBsum; 1LWE; -.
DR   PDBsum; 1LWF; -.
DR   PDBsum; 1NCP; -.
DR   PDBsum; 1O1W; -.
DR   PDBsum; 1ODW; -.
DR   PDBsum; 1ODY; -.
DR   PDBsum; 1QBR; -.
DR   PDBsum; 1QBS; -.
DR   PDBsum; 1QBT; -.
DR   PDBsum; 1QBU; -.
DR   PDBsum; 1REV; -.
DR   PDBsum; 1RT1; -.
DR   PDBsum; 1RT2; -.
DR   PDBsum; 1RT3; -.
DR   PDBsum; 1RT4; -.
DR   PDBsum; 1RT5; -.
DR   PDBsum; 1RT6; -.
DR   PDBsum; 1RT7; -.
DR   PDBsum; 1RTD; -.
DR   PDBsum; 1RTH; -.
DR   PDBsum; 1RTI; -.
DR   PDBsum; 1RTJ; -.
DR   PDBsum; 1S1T; -.
DR   PDBsum; 1S1U; -.
DR   PDBsum; 1S1V; -.
DR   PDBsum; 1S1W; -.
DR   PDBsum; 1S1X; -.
DR   PDBsum; 1T05; -.
DR   PDBsum; 1TAM; -.
DR   PDBsum; 1TKT; -.
DR   PDBsum; 1TKX; -.
DR   PDBsum; 1TKZ; -.
DR   PDBsum; 1TL1; -.
DR   PDBsum; 1TL3; -.
DR   PDBsum; 1VRT; -.
DR   PDBsum; 1VRU; -.
DR   PDBsum; 2HND; -.
DR   PDBsum; 2HNY; -.
DR   PDBsum; 2HNZ; -.
DR   PDBsum; 2KOD; -.
DR   PDBsum; 2NPH; -.
DR   PDBsum; 2OPP; -.
DR   PDBsum; 2OPQ; -.
DR   PDBsum; 2OPR; -.
DR   PDBsum; 2OPS; -.
DR   PDBsum; 2RF2; -.
DR   PDBsum; 2RKI; -.
DR   PDBsum; 2WHH; -.
DR   PDBsum; 2WOM; -.
DR   PDBsum; 2WON; -.
DR   PDBsum; 2YNF; -.
DR   PDBsum; 2YNG; -.
DR   PDBsum; 2YNH; -.
DR   PDBsum; 2YNI; -.
DR   PDBsum; 3AO2; -.
DR   PDBsum; 3C6T; -.
DR   PDBsum; 3C6U; -.
DR   PDBsum; 3DI6; -.
DR   PDBsum; 3DLE; -.
DR   PDBsum; 3DLG; -.
DR   PDBsum; 3DM2; -.
DR   PDBsum; 3DMJ; -.
DR   PDBsum; 3DOK; -.
DR   PDBsum; 3DOL; -.
DR   PDBsum; 3DOX; -.
DR   PDBsum; 3DRP; -.
DR   PDBsum; 3DRR; -.
DR   PDBsum; 3DRS; -.
DR   PDBsum; 3DYA; -.
DR   PDBsum; 3E01; -.
DR   PDBsum; 3FFI; -.
DR   PDBsum; 3I0R; -.
DR   PDBsum; 3I0S; -.
DR   PDBsum; 3KJV; -.
DR   PDBsum; 3KK1; -.
DR   PDBsum; 3KK2; -.
DR   PDBsum; 3KK3; -.
DR   PDBsum; 3KT2; -.
DR   PDBsum; 3KT5; -.
DR   PDBsum; 3LAK; -.
DR   PDBsum; 3LAL; -.
DR   PDBsum; 3LAM; -.
DR   PDBsum; 3LAN; -.
DR   PDBsum; 3LP0; -.
DR   PDBsum; 3LP1; -.
DR   PDBsum; 3LP2; -.
DR   PDBsum; 3M8P; -.
DR   PDBsum; 3M8Q; -.
DR   PDBsum; 3MEC; -.
DR   PDBsum; 3MED; -.
DR   PDBsum; 3MEE; -.
DR   PDBsum; 3MEG; -.
DR   PDBsum; 3MIM; -.
DR   PDBsum; 3N3I; -.
DR   PDBsum; 3NBP; -.
DR   PDBsum; 3PHV; -.
DR   PDBsum; 3QIN; -.
DR   PDBsum; 3QIO; -.
DR   PDBsum; 3QIP; -.
DR   PDBsum; 3T19; -.
DR   PDBsum; 3T1A; -.
DR   PDBsum; 3TAM; -.
DR   PDBsum; 4B3O; -.
DR   PDBsum; 4B3P; -.
DR   PDBsum; 4B3Q; -.
DR   PDBsum; 4I7F; -.
DR   PDBsum; 4KSE; -.
DR   PDBsum; 4KV8; -.
DR   PDBsum; 4NCG; -.
DR   PDBsum; 4Q5M; -.
DR   PDBsum; 4QLH; -.
DR   ProteinModelPortal; P04585; -.
DR   SMR; P04585; 1-432, 489-1144, 1148-1417.
DR   BioGrid; 1205538; 126.
DR   IntAct; P04585; 6.
DR   MINT; MINT-111862; -.
DR   BindingDB; P04585; -.
DR   GeneID; 155348; -.
DR   KEGG; vg:155348; -.
DR   BRENDA; 2.7.7.49; 2676.
DR   BRENDA; 3.4.23.16; 2676.
DR   Reactome; REACT_6266; Early Phase of HIV Life Cycle.
DR   Reactome; REACT_6359; Budding and maturation of HIV virion.
DR   Reactome; REACT_6818; Assembly Of The HIV Virion.
DR   Reactome; REACT_6866; Autointegration results in viral DNA circles.
DR   Reactome; REACT_6903; Binding and entry of HIV virion.
DR   Reactome; REACT_6918; Integration of provirus.
DR   Reactome; REACT_6965; Uncoating of the HIV Virion.
DR   Reactome; REACT_7991; Vpr-mediated nuclear import of PICs.
DR   Reactome; REACT_8990; Integration of viral DNA into host genomic DNA.
DR   Reactome; REACT_9037; Plus-strand DNA synthesis.
DR   Reactome; REACT_9055; Minus-strand DNA synthesis.
DR   Reactome; REACT_9058; 2-LTR circle formation.
DR   Reactome; REACT_9406; APOBEC3G mediated resistance to HIV-1 infection.
DR   SABIO-RK; P04585; -.
DR   EvolutionaryTrace; P04585; -.
DR   PRO; PR:P04585; -.
DR   Proteomes; UP000002241; Genome.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0072494; C:host multivesicular body; IEA:UniProtKB-SubCell.
DR   GO; GO:0019013; C:viral nucleocapsid; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004190; F:aspartic-type endopeptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003887; F:DNA-directed DNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004533; F:exoribonuclease H activity; IEA:UniProtKB-EC.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003964; F:RNA-directed DNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004523; F:RNA-DNA hybrid ribonuclease activity; IEA:InterPro.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0015074; P:DNA integration; IEA:UniProtKB-KW.
DR   GO; GO:0006310; P:DNA recombination; IEA:UniProtKB-KW.
DR   GO; GO:0030260; P:entry into host cell; TAS:Reactome.
DR   GO; GO:0075713; P:establishment of integrated proviral latency; TAS:Reactome.
DR   GO; GO:0039651; P:induction by virus of host cysteine-type endopeptidase activity involved in apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0006278; P:RNA-dependent DNA replication; TAS:Reactome.
DR   GO; GO:0039657; P:suppression by virus of host gene expression; IEA:UniProtKB-KW.
DR   GO; GO:0019061; P:uncoating of virus; TAS:Reactome.
DR   GO; GO:0046718; P:viral entry into host cell; IEA:UniProtKB-KW.
DR   GO; GO:0019058; P:viral life cycle; TAS:Reactome.
DR   GO; GO:0075732; P:viral penetration into host nucleus; IEA:UniProtKB-KW.
DR   GO; GO:0016032; P:viral process; TAS:Reactome.
DR   GO; GO:0019076; P:viral release from host cell; IEA:UniProtKB-KW.
DR   GO; GO:0019068; P:virion assembly; TAS:Reactome.
DR   Gene3D; 1.10.10.200; -; 1.
DR   Gene3D; 1.10.1200.30; -; 1.
DR   Gene3D; 1.10.150.90; -; 1.
DR   Gene3D; 1.10.375.10; -; 1.
DR   Gene3D; 2.30.30.10; -; 1.
DR   Gene3D; 2.40.70.10; -; 1.
DR   Gene3D; 3.30.420.10; -; 2.
DR   Gene3D; 4.10.60.10; -; 1.
DR   InterPro; IPR001969; Aspartic_peptidase_AS.
DR   InterPro; IPR000721; Gag_p24.
DR   InterPro; IPR001037; Integrase_C_retrovir.
DR   InterPro; IPR001584; Integrase_cat-core.
DR   InterPro; IPR017856; Integrase_Zn-bd_dom-like_N.
DR   InterPro; IPR003308; Integrase_Zn-bd_dom_N.
DR   InterPro; IPR000071; Lentvrl_matrix_N.
DR   InterPro; IPR012344; Matrix_HIV/RSV.
DR   InterPro; IPR018061; Pept_A2A_retrovirus_sg.
DR   InterPro; IPR001995; Peptidase_A2_cat.
DR   InterPro; IPR021109; Peptidase_aspartic_dom.
DR   InterPro; IPR008916; Retrov_capsid_C.
DR   InterPro; IPR008919; Retrov_capsid_N.
DR   InterPro; IPR010999; Retrovr_matrix.
DR   InterPro; IPR012337; RNaseH-like_dom.
DR   InterPro; IPR002156; RNaseH_domain.
DR   InterPro; IPR000477; RT_dom.
DR   InterPro; IPR010659; RVT_connect.
DR   InterPro; IPR010661; RVT_thumb.
DR   InterPro; IPR001878; Znf_CCHC.
DR   Pfam; PF00540; Gag_p17; 1.
DR   Pfam; PF00607; Gag_p24; 1.
DR   Pfam; PF00552; IN_DBD_C; 1.
DR   Pfam; PF02022; Integrase_Zn; 1.
DR   Pfam; PF00075; RNase_H; 1.
DR   Pfam; PF00665; rve; 1.
DR   Pfam; PF00077; RVP; 1.
DR   Pfam; PF00078; RVT_1; 1.
DR   Pfam; PF06815; RVT_connect; 1.
DR   Pfam; PF06817; RVT_thumb; 1.
DR   Pfam; PF00098; zf-CCHC; 2.
DR   PRINTS; PR00234; HIV1MATRIX.
DR   SMART; SM00343; ZnF_C2HC; 2.
DR   SUPFAM; SSF46919; SSF46919; 1.
DR   SUPFAM; SSF47353; SSF47353; 1.
DR   SUPFAM; SSF47836; SSF47836; 1.
DR   SUPFAM; SSF47943; SSF47943; 1.
DR   SUPFAM; SSF50122; SSF50122; 1.
DR   SUPFAM; SSF50630; SSF50630; 1.
DR   SUPFAM; SSF53098; SSF53098; 2.
DR   SUPFAM; SSF57756; SSF57756; 1.
DR   PROSITE; PS50175; ASP_PROT_RETROV; 1.
DR   PROSITE; PS00141; ASP_PROTEASE; 1.
DR   PROSITE; PS50994; INTEGRASE; 1.
DR   PROSITE; PS51027; INTEGRASE_DBD; 1.
DR   PROSITE; PS50879; RNASE_H; 1.
DR   PROSITE; PS50878; RT_POL; 1.
DR   PROSITE; PS50158; ZF_CCHC; 2.
DR   PROSITE; PS50876; ZF_INTEGRASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activation of host caspases by virus; AIDS;
KW   Aspartyl protease; Capsid protein; Complete proteome; DNA integration;
KW   DNA recombination; DNA-binding; DNA-directed DNA polymerase;
KW   Endonuclease; Eukaryotic host gene expression shutoff by virus;
KW   Eukaryotic host translation shutoff by virus; Host cell membrane;
KW   Host cytoplasm; Host endosome; Host gene expression shutoff by virus;
KW   Host membrane; Host nucleus; Host-virus interaction; Hydrolase;
KW   Lipid-binding; Lipoprotein; Magnesium; Membrane; Metal-binding;
KW   Modulation of host cell apoptosis by virus; Multifunctional enzyme;
KW   Myristate; Nuclease; Nucleotidyltransferase; Phosphoprotein; Protease;
KW   Reference proteome; Repeat; Ribosomal frameshifting; RNA-binding;
KW   RNA-directed DNA polymerase; Transferase; Viral genome integration;
KW   Viral nucleoprotein; Viral penetration into host nucleus; Virion;
KW   Virion maturation; Virus entry into host cell;
KW   Virus exit from host cell; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed; by host. {ECO:0000250}.
FT   CHAIN         2   1435       Gag-Pol polyprotein.
FT                                /FTId=PRO_0000223620.
FT   CHAIN         2    132       Matrix protein p17. {ECO:0000250}.
FT                                /FTId=PRO_0000042439.
FT   CHAIN       133    363       Capsid protein p24. {ECO:0000250}.
FT                                /FTId=PRO_0000042440.
FT   PEPTIDE     364    377       Spacer peptide 1. {ECO:0000250}.
FT                                /FTId=PRO_0000042441.
FT   CHAIN       378    432       Nucleocapsid protein p7. {ECO:0000250}.
FT                                /FTId=PRO_0000042442.
FT   PEPTIDE     433    440       Transframe peptide. {ECO:0000255}.
FT                                /FTId=PRO_0000246716.
FT   CHAIN       441    488       p6-pol. {ECO:0000255}.
FT                                /FTId=PRO_0000042443.
FT   CHAIN       489    587       Protease.
FT                                /FTId=PRO_0000038665.
FT   CHAIN       588   1147       Reverse transcriptase/ribonuclease H.
FT                                /FTId=PRO_0000042444.
FT   CHAIN       588   1027       p51 RT.
FT                                /FTId=PRO_0000042445.
FT   CHAIN      1028   1147       p15.
FT                                /FTId=PRO_0000042446.
FT   CHAIN      1148   1435       Integrase. {ECO:0000250}.
FT                                /FTId=PRO_0000042447.
FT   DOMAIN      508    577       Peptidase A2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00275}.
FT   DOMAIN      631    821       Reverse transcriptase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00405}.
FT   DOMAIN     1021   1144       RNase H. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00408}.
FT   DOMAIN     1201   1351       Integrase catalytic.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00457}.
FT   ZN_FING     390    407       CCHC-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00047}.
FT   ZN_FING     411    428       CCHC-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00047}.
FT   ZN_FING    1150   1191       Integrase-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00450}.
FT   DNA_BIND   1370   1417       Integrase-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00506}.
FT   REGION        7     31       Interaction with Gp41.
FT                                {ECO:0000250|UniProtKB:P12497}.
FT   REGION        8     43       Interaction with host CALM1.
FT                                {ECO:0000269|PubMed:24500712}.
FT   REGION       12     19       Interaction with host AP3D1.
FT                                {ECO:0000250|UniProtKB:P12497}.
FT   REGION       14     33       Interaction with membrane
FT                                phosphatidylinositol 4,5-bisphosphate and
FT                                RNA. {ECO:0000250|UniProtKB:P12497}.
FT   REGION       73     77       Interaction with membrane
FT                                phosphatidylinositol 4,5-bisphosphate.
FT                                {ECO:0000250|UniProtKB:P12497}.
FT   REGION      189    227       Interaction with host PPIA/CYPA and
FT                                NUP153. {ECO:0000250|UniProtKB:P12497}.
FT   REGION      217    225       PPIA/CYPA-binding loop.
FT   REGION      277    363       Dimerization/Multimerization of capsid
FT                                protein p24.
FT   REGION      489    493       Dimerization of protease.
FT                                {ECO:0000269|PubMed:2162350}.
FT   REGION      537    543       Dimerization of protease.
FT                                {ECO:0000269|PubMed:2162350}.
FT   REGION      576    588       Dimerization of protease.
FT                                {ECO:0000269|PubMed:2162350}.
FT   REGION      814    822       RT 'primer grip'. {ECO:0000250}.
FT   MOTIF        16     22       Nuclear export signal. {ECO:0000250}.
FT   MOTIF        26     32       Nuclear localization signal.
FT                                {ECO:0000250}.
FT   MOTIF       985   1001       Tryptophan repeat motif. {ECO:0000250}.
FT   ACT_SITE    513    513       For protease activity; shared with
FT                                dimeric partner. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10094}.
FT   METAL       697    697       Magnesium; catalytic; for reverse
FT                                transcriptase activity. {ECO:0000250}.
FT   METAL       772    772       Magnesium; catalytic; for reverse
FT                                transcriptase activity. {ECO:0000250}.
FT   METAL       773    773       Magnesium; catalytic; for reverse
FT                                transcriptase activity. {ECO:0000250}.
FT   METAL      1030   1030       Magnesium; catalytic; for RNase H
FT                                activity.
FT   METAL      1065   1065       Magnesium; catalytic; for RNase H
FT                                activity. {ECO:0000269|PubMed:12206668}.
FT   METAL      1085   1085       Magnesium; catalytic; for RNase H
FT                                activity.
FT   METAL      1136   1136       Magnesium; catalytic; for RNase H
FT                                activity. {ECO:0000269|PubMed:12206668}.
FT   METAL      1211   1211       Magnesium; catalytic; for integrase
FT                                activity. {ECO:0000250}.
FT   METAL      1263   1263       Magnesium; catalytic; for integrase
FT                                activity. {ECO:0000250}.
FT   METAL      1299   1299       Magnesium; catalytic; for integrase
FT                                activity. {ECO:0000305}.
FT   SITE        132    133       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        221    222       Cis/trans isomerization of proline
FT                                peptide bond; by human PPIA/CYPA.
FT   SITE        363    364       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        377    378       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        393    394       Cleavage; by viral protease.
FT                                {ECO:0000255}.
FT   SITE        426    427       Cleavage; by viral protease.
FT                                {ECO:0000255}.
FT   SITE        432    433       Cleavage; by viral protease.
FT                                {ECO:0000255}.
FT   SITE        440    441       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        488    489       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        587    588       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   SITE        988    988       Essential for RT p66/p51
FT                                heterodimerization. {ECO:0000250}.
FT   SITE       1001   1001       Essential for RT p66/p51
FT                                heterodimerization. {ECO:0000250}.
FT   SITE       1027   1028       Cleavage; by viral protease; partial.
FT                                {ECO:0000250}.
FT   SITE       1147   1148       Cleavage; by viral protease.
FT                                {ECO:0000250}.
FT   MOD_RES     132    132       Phosphotyrosine; by host. {ECO:0000250}.
FT   LIPID         2      2       N-myristoyl glycine; by host.
FT                                {ECO:0000250}.
FT   VARIANT     496    496       R -> K (confers to resistance to A-77003;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     496    496       R -> Q (confers to resistance to A-
FT                                77003).
FT   VARIANT     498    498       L -> F (confers resistance to amprenavir,
FT                                atazanavir, lopinavir; when associated
FT                                with other amino acid changes).
FT   VARIANT     498    498       L -> I (confers resistance to indinavir,
FT                                lopinavir, ritonavir and saquinavir; when
FT                                associated with other amino acid
FT                                changes).
FT   VARIANT     498    498       L -> R (confers resistance to indinavir
FT                                and lopinavir; when associated with other
FT                                amino acid changes).
FT   VARIANT     498    498       L -> V (confers resistance to indinavir
FT                                and lopinavir; when associated with other
FT                                amino acid changes).
FT   VARIANT     498    498       L -> Y (confers resistance to atazanavir;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     503    503       I -> V (confers resistance to
FT                                tipranavir).
FT   VARIANT     504    504       G -> E (confers resistance to lopinavir,
FT                                ritonavir and saquinavir; when associated
FT                                with other amino acid changes).
FT   VARIANT     508    508       K -> I (confers resistance to lopinavir).
FT   VARIANT     508    508       K -> M (confers resistance to indinavir,
FT                                lopinavir and nelfinavir; when associated
FT                                with other amino acid changes).
FT   VARIANT     508    508       K -> R (confers resistance to indinavir,
FT                                lopinavir and ritonavir; when associated
FT                                with other amino acid changes).
FT   VARIANT     511    511       L -> I (confers resistance to BILA 2185
FT                                BS).
FT   VARIANT     512    512       L -> I (confers resistance to amprenavir,
FT                                indinavir, lopinavir, ritonavir and
FT                                saquinavir; when associated with other
FT                                amino acid changes).
FT   VARIANT     518    518       D -> N (confers resistance to nelfinavir;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     520    520       V -> I (confers resistance to A-77003,
FT                                amprenavir, atazanavir, indinavir,
FT                                kynostatin, lopinavir, ritonavir and
FT                                saquinavir; when associated with other
FT                                amino acid changes).
FT   VARIANT     521    521       L -> F (confers resistance to atazanavir
FT                                nelfinavir and ritonavir; when associated
FT                                with other amino acid changes).
FT   VARIANT     522    522       E -> Q (confers resistance to lopinavir;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     523    523       E -> D (confers resistance to
FT                                tipranavir).
FT   VARIANT     524    524       M -> I (confers resistance to nelfinavir
FT                                and ritonavir; when associated with other
FT                                amino acid changes).
FT   VARIANT     524    524       M -> L (confers resistance to ritonavir;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     525    525       S -> D (confers resistance to indinavir
FT                                and tipranavir; when associated with
FT                                other amino acid changes).
FT   VARIANT     529    529       R -> K (confers resistance to
FT                                tipranavir).
FT   VARIANT     533    533       K -> I (confers resistance to DMD-323;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     534    534       M -> F (confers resistance to A-77003).
FT   VARIANT     534    534       M -> I (confers resistance to A-77003,
FT                                amprenavir, atazanavir, indinavir,
FT                                kynostatin, lopinavir, ritonavir,
FT                                saquinavir and telinavir; when associated
FT                                with other amino acid changes).
FT   VARIANT     534    534       M -> L (confers resistance to A-77003,
FT                                amprenavir, indinavir, lopinavir,
FT                                ritonavir and saquinavir; when associated
FT                                with other amino acid changes).
FT   VARIANT     535    535       I -> V (confers resistance to amprenavir,
FT                                lopinavir, kynostatin, ritonavir and
FT                                saquinavir; when associated with other
FT                                amino acid changes).
FT   VARIANT     536    536       G -> V (confers resistance to A-77003,
FT                                amprenavir, indinavir, ritonavir,
FT                                saquinavir and telinavir; when associated
FT                                with other amino acid changes).
FT   VARIANT     538    538       I -> L (confers resistance to atazanavir;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     538    538       I -> V (confers resistance to amprenavir,
FT                                lopinavir and ritonavir; when associated
FT                                with other amino acid changes).
FT   VARIANT     541    541       F -> L (confers resistance to lopinavir
FT                                and telinavir; when associated with other
FT                                amino acid changes).
FT   VARIANT     541    541       F -> Y (confers resistance to indinavir,
FT                                ritonavir and saquinavir; when associated
FT                                with other amino acid changes).
FT   VARIANT     542    542       I -> A (confers resistance to lopinavir).
FT   VARIANT     542    542       I -> L (confers resistance to amprenavir
FT                                and lopinavir; when associated with other
FT                                amino acid changes).
FT   VARIANT     542    542       I -> M (confers resistance to amprenavir
FT                                and lopinavir).
FT   VARIANT     542    542       I -> S (confers resistance to lopinavir).
FT   VARIANT     542    542       I -> T (confers resistance to lopinavir;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     542    542       I -> V (confers resistance to indinavir,
FT                                lopinavir, ritonavir and saquinavir; when
FT                                associated with other amino acid
FT                                changes).
FT   VARIANT     543    543       K -> R (confers resistance to
FT                                nelfinavir).
FT   VARIANT     545    545       R -> K (confers resistance to
FT                                nelfinavir).
FT   VARIANT     546    546       Q -> E (confers resistance to lopinavir
FT                                and ritonavir; when associated with other
FT                                amino acid changes).
FT   VARIANT     548    548       D -> E (confers resistance to
FT                                tripanavir).
FT   VARIANT     549    549       Q -> H (confers resistance to lopinavir;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     551    551       L -> P (confers resistance to atazanavir,
FT                                indinavir, lopinavir, ritonavir and
FT                                saquinavir; when associated with other
FT                                amino acid changes).
FT   VARIANT     551    551       L -> T (confers resistance to lopinavir).
FT   VARIANT     553    553       E -> Q (confers resistance to lopinavir;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     554    554       I -> F (confers resistance to indinavir,
FT                                ritonavir and saquinavir; when associated
FT                                with other amino acid changes).
FT   VARIANT     557    557       H -> Y (confers resistance to lopinavir;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     559    559       A -> I (confers resistance to lopinavir;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     559    559       A -> L (confers resistance to lopinavir;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     559    559       A -> T (confers resistance to A-77003,
FT                                indinavir, lopinavir, nelfinavir and
FT                                tripanavir; when associated with other
FT                                amino acid changes).
FT   VARIANT     559    559       A -> V (confers resistance to amprenavir,
FT                                atazanavir, indinavir, kynostatin,
FT                                lopinavir, nelfinavir, ritonavir,
FT                                saquinavir and telinavir; when associated
FT                                with other amino acid changes).
FT   VARIANT     561    561       G -> S (confers resistance to indinavir,
FT                                nelfinavir, ritonavir and saquinavir;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     565    565       V -> I (confers resistance to indinavir,
FT                                nelfinavir, ritonavir and saquinavir;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     570    570       V -> A (confers resistance to A-77003,
FT                                indinavir, lopinavir, nelfinavir,
FT                                ritonavir and saquinavir; when associated
FT                                with other amino acid changes).
FT   VARIANT     570    570       V -> F (confers resistance to lopinavir
FT                                and ritonavir; when associated with other
FT                                amino acid changes).
FT   VARIANT     570    570       V -> I (confers resistance to A-77003 and
FT                                kynostatin; when associated with other
FT                                amino acid changes).
FT   VARIANT     570    570       V -> S (confers resistance to lopinavir
FT                                and ritonavir).
FT   VARIANT     570    570       V -> T (confers resistance to indinavir,
FT                                lopinavir, ritonavir and saquinavir; when
FT                                associated with other amino acid
FT                                changes).
FT   VARIANT     572    572       I -> A (confers resistance to atazanavir,
FT                                indinavir, lopinavir, nelfinavir,
FT                                ritonavir and saquinavir; when associated
FT                                with other amino acid changes).
FT   VARIANT     572    572       I -> V (confers resistance to amprenavir,
FT                                atazanavir, indinavir, kynostatin,
FT                                lopinavir, nelfinavir, ritonavir,
FT                                saquinavir and telinavir; when associated
FT                                with other amino acid changes).
FT   VARIANT     576    576       N -> D (confers resistance to nelfinavir;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     576    576       N -> S (confers resistance to atazanavir,
FT                                indinavir and nelfinavir; when associated
FT                                with other amino acid changes).
FT   VARIANT     577    577       L -> M (confers resistance to atazanavir;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     578    578       L -> M (confers resistance to indinavir,
FT                                lopinavir, nelfinavir, ritonavir and
FT                                saquinavir; when associated with other
FT                                amino acid changes).
FT   VARIANT     579    579       T -> S (confers resistance to lopinavir,
FT                                ritonavir and saquinavir; when associated
FT                                with other amino acid changes).
FT   VARIANT     581    581       I -> L (confers resistance to indinavir).
FT   VARIANT     628    628       M -> L (confers resistance to zidovudine;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     631    631       E -> A (confers resistance to
FT                                lamivudine).
FT   VARIANT     631    631       E -> D (confers resistance to zidovudine;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     639    639       P -> R (confers resistance to stavudine).
FT   VARIANT     641    641       N -> D (confers resistance to stavudine).
FT   VARIANT     649    649       A -> V (confers multi-NRTI resistance;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     652    652       K -> R (confers resistance to abacavir,
FT                                adefovir, didenosine, lamivudine,
FT                                stavudine, tenofir and zidovuline; when
FT                                associated with other amino acid
FT                                changes).
FT   VARIANT     654    654       D -> A (confers resistance to
FT                                zidovudine).
FT   VARIANT     654    654       D -> E (confers multi-NRTI resistance).
FT   VARIANT     654    654       D -> G (confers multi-NRTI resistance).
FT   VARIANT     654    654       D -> N (confers resistance to
FT                                zidovudine).
FT   VARIANT     654    654       D -> S (confers multi-NRTI resistance).
FT   VARIANT     655    655       S -> G (confers multi-NRTI resistance;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     655    655       S -> N (confers multi-NRTI resistance).
FT   VARIANT     655    655       S -> Y (confers multi-NRTI resistance).
FT   VARIANT     656    656       T -> A (confers resistance to lamivudine
FT                                and stavudine).
FT   VARIANT     656    656       T -> D (confers resistance to lamivudine,
FT                                stavudine and rarely to zalcitabine).
FT   VARIANT     656    656       T -> G (confers resistance to didanosine,
FT                                zalcitabine and zidovudine).
FT   VARIANT     656    656       T -> N (confers resistance to lamivudine
FT                                and stavudine).
FT   VARIANT     657    657       K -> E (confers resistance to adefovir
FT                                and lamivudine).
FT   VARIANT     657    657       K -> R (confers resistance to zidovudine;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     657    657       K -> S (confers resistance to didanosine
FT                                and stavudine).
FT   VARIANT     661    661       L -> I (confers resistance to HBY 097).
FT   VARIANT     661    661       L -> V (confers resistance to abacavir,
FT                                didanosine, HBY 097 and zalcitabine; when
FT                                associated with other amino acid
FT                                changes).
FT   VARIANT     662    662       V -> I (confers multi-NRTI resistance;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     662    662       V -> L (confers resistance to HBY 097).
FT   VARIANT     662    662       V -> M (confers resistance to stavudine
FT                                and zalcitabine).
FT   VARIANT     662    662       V -> T (confers resistance to d4C,
FT                                didanosine, stavudine and zalcitabine).
FT   VARIANT     664    664       F -> L (confers multi-NRTI resistance;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     675    675       W -> G (confers resistance to
FT                                pyrophosphate analog PFA).
FT   VARIANT     675    675       W -> S (confers resistance to
FT                                pyrophosphate analog PFA).
FT   VARIANT     676    676       E -> G (confers resistance to
FT                                pyrophosphate analog PFA).
FT   VARIANT     676    676       E -> K (confers resistance to
FT                                pyrophosphate analog PFA).
FT   VARIANT     679    679       L -> I (confers resistance to
FT                                pyrophosphate analog PFA).
FT   VARIANT     687    687       L -> I (confers resistance to nevirapine
FT                                and efavirenz).
FT   VARIANT     688    688       K -> E (confers resistance to atevirdine,
FT                                efavirenz, nevirapine and zidovudine).
FT   VARIANT     688    688       K -> P (confers resistance to TMC125;
FT                                when associated with E-142).
FT   VARIANT     688    688       K -> Q (confers resistance to efavirenz;
FT                                when associated with I-19).
FT   VARIANT     690    690       K -> E (confers resistance to atevirdine;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     690    690       K -> N (confers resistance to atevirdine,
FT                                efavirenz, emivirine and nevirapine; when
FT                                associated with other amino acid
FT                                changes).
FT   VARIANT     690    690       K -> R (confers resistance to emivirine
FT                                and trovirdine; when associated with
FT                                other D-179 and C-181).
FT   VARIANT     693    693       V -> A (confers resistance to
FT                                nevirapine).
FT   VARIANT     693    693       V -> I (confers resistance to HBY 097).
FT   VARIANT     693    693       V -> M (confers resistance to
FT                                delavirdine, efavirenz and nevirapine).
FT   VARIANT     695    695       V -> I (confers resistance to efavirenz,
FT                                emivirine, nevirapine and trovirdine;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     702    702       Y -> F (confers resistance to abacavir;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     703    703       F -> Y (confers multi-NRTI resistance;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     705    705       V -> I (confers resistance to zidovudine;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     706    706       P -> S (confers resistance to
FT                                lodenosine).
FT   VARIANT     722    722       I -> L (confers resistance to
FT                                delavirdine, efavirenz and nevirapine;
FT                                when associated with I-239).
FT   VARIANT     722    722       I -> M (confers resistance to
FT                                delavirdine, efavirenz and nevirapine;
FT                                when associated with I-239).
FT   VARIANT     722    722       I -> T (confers resistance to
FT                                delavirdine, efavirenz and nevirapine;
FT                                when associated with I-239).
FT   VARIANT     725    725       E -> K (confers resistance to emivirine).
FT   VARIANT     732    732       Q -> M (confers both multi-NRTI and
FT                                multi-NNRTI resistance).
FT   VARIANT     738    738       Q -> M (confers multi-NRTI resistance;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     743    743       S -> A (confers resistance to
FT                                pyrophosphate analog PFA).
FT   VARIANT     744    744       P -> S (confers resistance to
FT                                lamivudine).
FT   VARIANT     748    748       Q -> L (confers resistance to
FT                                pyrophosphate analog PFA).
FT   VARIANT     766    766       V -> D (confers resistance to efavirenz,
FT                                tivirapine and trovirdine; when
FT                                associated with other amino acid
FT                                changes).
FT   VARIANT     768    768       Y -> C (confers multi-NNRTI resistance).
FT   VARIANT     771    771       M -> I (confers resistance to lamivudine
FT                                and emtricitabine).
FT   VARIANT     771    771       M -> T (confers resistance to abacavir,
FT                                didanosine, emtricitabine, lamivudine and
FT                                zalcitabine).
FT   VARIANT     771    771       M -> V (confers resistance to
FT                                lamivudine).
FT   VARIANT     775    775       Y -> C (confers resistance to
FT                                nevirapine).
FT   VARIANT     775    775       Y -> H (confers resistance to atevirdine,
FT                                efavirenz, loviride and zidovudine).
FT   VARIANT     775    775       Y -> L (confers resistance to efavirenz).
FT   VARIANT     776    776       V -> I (confers resistance to HBY 097).
FT   VARIANT     777    777       G -> A (confers resistance to efavirenz
FT                                and nevirapine).
FT   VARIANT     777    777       G -> C (confers resistance to efavirenz
FT                                and nevirapine).
FT   VARIANT     777    777       G -> E (confers resistance to efavirenz,
FT                                nevirapine and quinoxaline).
FT   VARIANT     777    777       G -> Q (confers resistance to efavirenz,
FT                                HBY 097 and nevirapine).
FT   VARIANT     777    777       G -> S (confers resistance to efavirenz
FT                                and nevirapine).
FT   VARIANT     777    777       G -> T (confers resistance to efavirenz,
FT                                HBY 097 and nevirapine).
FT   VARIANT     777    777       G -> V (confers resistance to efavirenz
FT                                and nevirapine).
FT   VARIANT     795    795       H -> Y (confers resistance to lamivudine,
FT                                pyrophosphate analog PFA and zidovudine).
FT   VARIANT     797    797       L -> W (confers resistance to
FT                                zidovudine).
FT   VARIANT     798    798       R -> K (confers resistance to lamivudine
FT                                and zidovudine).
FT   VARIANT     801    801       L -> F (confers resistance to ph-AZT and
FT                                zidovudine).
FT   VARIANT     802    802       T -> F (confers resistance to zidovudine;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     802    802       T -> Y (confers resistance to zidovudine;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     806    806       K -> E (confers resistance to
FT                                zidovudine).
FT   VARIANT     806    806       K -> Q (confers resistance to zidovudine;
FT                                when associated with other amino acid
FT                                changes).
FT   VARIANT     806    806       K -> R (confers resistance to lamivudine,
FT                                stavudine, zalcicabine and zidovudine).
FT   VARIANT     812    812       P -> H (confers resistance to efavirenz,
FT                                emivirine, HBY 097 and quinoxaline; when
FT                                associated with A-17).
FT   VARIANT     823    823       P -> L (confers resistance to atevirdine
FT                                and delavirdine).
FT   VARIANT     825    825       K -> T (confers resistance to atevirdine
FT                                and zidovudine; when associated with
FT                                other amino acid changes).
FT   VARIANT     870    870       L -> I (confers resistance to
FT                                delavirdine, efavirenz and nevirapine).
FT   VARIANT     905    905       Y -> F (confers resistance to delavirdine
FT                                and nevirapine).
FT   VARIANT     920    920       G -> D (confers resistance to abacavir,
FT                                lamivudine and zidovudine).
FT   VARIANT     920    920       G -> E (confers resistance to abacavir,
FT                                lamivudine and zidovudine).
FT   VARIANT     973    973       T -> I (confers resistance to abacavir,
FT                                lamivudine and zidovudine).
FT   MUTAGEN       6      6       S->D: No influence on the PIP2- or
FT                                concentration-dependent myristyl switch
FT                                mechanism. {ECO:0000269|PubMed:17656588}.
FT   MUTAGEN       9      9       S->D: No influence on the PIP2- or
FT                                concentration-dependent myristyl switch
FT                                mechanism. {ECO:0000269|PubMed:17656588}.
FT   MUTAGEN      18     18       K->A: Replication-defective, induces
FT                                nuclear mislocalization of matrix
FT                                protein; when associated with G-22.
FT                                {ECO:0000269|PubMed:10604476}.
FT   MUTAGEN      22     22       R->G: Replication-defective, induces
FT                                nuclear mislocalization of matrix
FT                                protein; when associated with A-18.
FT                                {ECO:0000269|PubMed:10604476}.
FT   MUTAGEN      27     27       K->A: No effect on subcellular
FT                                localization of matrix protein; when
FT                                associated with A-18 and G-22.
FT                                {ECO:0000269|PubMed:10604476}.
FT   MUTAGEN      67     67       S->D: No influence on the PIP2- or
FT                                concentration-dependent myristyl switch
FT                                mechanism. {ECO:0000269|PubMed:17656588}.
FT   MUTAGEN      72     72       S->D: No influence on the PIP2- or
FT                                concentration-dependent myristyl switch
FT                                mechanism. {ECO:0000269|PubMed:17656588}.
FT   MUTAGEN     217    217       P->A: 3-fold decrease of PPIA-binding
FT                                affinity. {ECO:0000269|PubMed:9223641}.
FT   MUTAGEN     218    218       V->A: 2.7-fold decrease of PPIA-binding
FT                                affinity. {ECO:0000269|PubMed:9223641}.
FT   MUTAGEN     219    219       H->A,Q: 8-fold decrease of PPIA-binding
FT                                affinity. {ECO:0000269|PubMed:9223641}.
FT   MUTAGEN     220    220       A->G: 44-fold decrease of PPIA-binding
FT                                affinity. {ECO:0000269|PubMed:9223641}.
FT   MUTAGEN     220    220       A->V: 3.4-fold decrease of PPIA-binding
FT                                affinity. {ECO:0000269|PubMed:9223641}.
FT   MUTAGEN     221    221       G->A: 31-fold decrease of PPIA-binding
FT                                affinity. {ECO:0000269|PubMed:9223641}.
FT   MUTAGEN     221    221       G->V: 154-fold decrease of PPIA-binding
FT                                affinity. {ECO:0000269|PubMed:9223641}.
FT   MUTAGEN     222    222       P->A: 36-fold decrease of PPIA-binding
FT                                affinity. {ECO:0000269|PubMed:9223641}.
FT   MUTAGEN     222    222       P->V: More than 150-fold decrease of
FT                                PPIA-binding affinity.
FT                                {ECO:0000269|PubMed:9223641}.
FT   MUTAGEN     223    223       I->A: 1.2-fold decrease of PPIA-binding
FT                                affinity. {ECO:0000269|PubMed:9223641}.
FT   MUTAGEN     223    223       I->V: 1.0-fold decrease of PPIA-binding
FT                                affinity. {ECO:0000269|PubMed:9223641}.
FT   MUTAGEN     224    224       A->G: 2.3-fold decrease of PPIA-binding
FT                                affinity. {ECO:0000269|PubMed:9223641}.
FT   MUTAGEN     224    224       A->V: 1.7-fold decrease of PPIA-binding
FT                                affinity. {ECO:0000269|PubMed:9223641}.
FT   MUTAGEN     225    225       P->A: 1.6-fold decrease of PPIA-binding
FT                                affinity. {ECO:0000269|PubMed:9223641}.
FT   MUTAGEN     394    394       N->F,G: Decreases infectivity and
FT                                replication.
FT                                {ECO:0000269|PubMed:16904152}.
FT   MUTAGEN     400    400       H->C: Complete loss of infectivity and in
FT                                vitro chaperone activity.
FT                                {ECO:0000269|PubMed:11932404}.
FT   MUTAGEN     405    405       C->H: Complete loss of infectivity and
FT                                DNA synthesis.
FT                                {ECO:0000269|PubMed:11932404}.
FT   MUTAGEN     421    421       H->C: Partial loss of infectivity.
FT                                Complete loss of in vitro chaperone
FT                                activity. {ECO:0000269|PubMed:11932404}.
FT   MUTAGEN     426    426       C->H: Partial loss of infectivity.
FT                                {ECO:0000269|PubMed:11932404}.
FT   MUTAGEN    1065   1065       E->Q: Complete loss of RNase H activity.
FT                                {ECO:0000269|PubMed:12206668}.
FT   MUTAGEN    1136   1136       D->N: Complete loss of RNase H activity.
FT                                {ECO:0000269|PubMed:12206668}.
FT   MUTAGEN    1159   1159       H->C: No effect on integrase activity in
FT                                vitro. {ECO:0000269|PubMed:8420982}.
FT   MUTAGEN    1163   1163       H->C,V: 75% increase of integrase
FT                                activity in vitro.
FT                                {ECO:0000269|PubMed:8420982}.
FT   MUTAGEN    1187   1187       C->A: Complete loss of integrase activity
FT                                in vivo. {ECO:0000269|PubMed:8035478}.
FT   MUTAGEN    1190   1190       C->A: Complete loss of integrase activity
FT                                in vivo. {ECO:0000269|PubMed:8035478}.
FT   MUTAGEN    1200   1200       Q->C: 75% increase of integrase activity
FT                                in vitro. {ECO:0000269|PubMed:8420982}.
FT   MUTAGEN    1208   1208       W->A: Complete loss of integrase activity
FT                                in vivo. {ECO:0000269|PubMed:8035478}.
FT   MUTAGEN    1211   1211       D->A,V: Complete loss of integrase
FT                                activity in vivo and in vitro.
FT                                {ECO:0000269|PubMed:8035478,
FT                                ECO:0000269|PubMed:8420982,
FT                                ECO:0000269|PubMed:9573231}.
FT   MUTAGEN    1213   1213       T->A: No effect on infectivity.
FT                                {ECO:0000269|PubMed:8035478}.
FT   MUTAGEN    1222   1222       V->P: Complete loss of integrase
FT                                activity. {ECO:0000269|PubMed:8035478}.
FT   MUTAGEN    1228   1228       S->A: Complete loss of integrase activity
FT                                in vivo. {ECO:0000269|PubMed:8035478,
FT                                ECO:0000269|PubMed:8420982}.
FT   MUTAGEN    1228   1228       S->R: No effect on integrase activity in
FT                                vitro. {ECO:0000269|PubMed:8035478,
FT                                ECO:0000269|PubMed:8420982}.
FT   MUTAGEN    1262   1262       T->A: No effect infectivity.
FT                                {ECO:0000269|PubMed:8035478}.
FT   MUTAGEN    1263   1263       D->A,I: Complete loss of integrase
FT                                activity in vivo and in vitro.
FT                                {ECO:0000269|PubMed:8035478,
FT                                ECO:0000269|PubMed:8420982,
FT                                ECO:0000269|PubMed:9573231}.
FT   MUTAGEN    1270   1270       G->A: No effect on infectivity.
FT                                {ECO:0000269|PubMed:8035478}.
FT   MUTAGEN    1282   1282       I->P: Complete loss of integrase activity
FT                                in vivo. {ECO:0000269|PubMed:8035478}.
FT   MUTAGEN    1298   1298       V->A: No effect on infectivity.
FT                                {ECO:0000269|PubMed:8035478}.
FT   MUTAGEN    1299   1299       E->G,P: Complete loss of integrase
FT                                activity in vitro.
FT                                {ECO:0000269|PubMed:8035478,
FT                                ECO:0000269|PubMed:8420982,
FT                                ECO:0000269|PubMed:9573231}.
FT   MUTAGEN    1306   1306       K->P: Slow down virus replication.
FT                                {ECO:0000269|PubMed:8035478}.
FT   MUTAGEN    1326   1326       A->P: Complete loss of integrase activity
FT                                in vivo. {ECO:0000269|PubMed:8035478}.
FT   MUTAGEN    1346   1346       R->C: 75% increase of integrase activity
FT                                in vitro. {ECO:0000269|PubMed:8420982}.
FT   MUTAGEN    1382   1382       W->A: Complete loss of infectivity. No
FT                                effect on integrase activity in vitro.
FT                                {ECO:0000269|PubMed:8035478,
FT                                ECO:0000269|PubMed:8420982}.
FT   MUTAGEN    1382   1382       W->E: 75% increase of integrase activity
FT                                in vitro. {ECO:0000269|PubMed:8035478,
FT                                ECO:0000269|PubMed:8420982}.
FT   STRAND        7     10       {ECO:0000244|PDB:1TAM}.
FT   HELIX        11     18       {ECO:0000244|PDB:1TAM}.
FT   STRAND       19     21       {ECO:0000244|PDB:1TAM}.
FT   STRAND       23     25       {ECO:0000244|PDB:1TAM}.
FT   HELIX        31     45       {ECO:0000244|PDB:1TAM}.
FT   STRAND       46     48       {ECO:0000244|PDB:1TAM}.
FT   TURN         50     52       {ECO:0000244|PDB:1TAM}.
FT   HELIX        54     67       {ECO:0000244|PDB:1TAM}.
FT   TURN         68     70       {ECO:0000244|PDB:1TAM}.
FT   HELIX        72     90       {ECO:0000244|PDB:1TAM}.
FT   HELIX        97    108       {ECO:0000244|PDB:1TAM}.
FT   HELIX       109    112       {ECO:0000244|PDB:1TAM}.
FT   STRAND      116    118       {ECO:0000244|PDB:1TAM}.
FT   HELIX       282    284       {ECO:0000244|PDB:2KOD}.
FT   HELIX       293    304       {ECO:0000244|PDB:2KOD}.
FT   HELIX       311    324       {ECO:0000244|PDB:2KOD}.
FT   HELIX       330    337       {ECO:0000244|PDB:2KOD}.
FT   HELIX       343    349       {ECO:0000244|PDB:2KOD}.
FT   TURN        350    353       {ECO:0000244|PDB:2KOD}.
FT   STRAND      357    360       {ECO:0000244|PDB:2KOD}.
FT   STRAND      393    395       {ECO:0000244|PDB:1ESK}.
FT   TURN        402    404       {ECO:0000244|PDB:1ESK}.
FT   STRAND      414    416       {ECO:0000244|PDB:1ESK}.
FT   TURN        423    425       {ECO:0000244|PDB:1ESK}.
FT   STRAND      485    487       {ECO:0000244|PDB:3KT2}.
FT   STRAND      491    495       {ECO:0000244|PDB:2NPH}.
FT   STRAND      498    503       {ECO:0000244|PDB:2NPH}.
FT   STRAND      506    512       {ECO:0000244|PDB:2NPH}.
FT   STRAND      516    518       {ECO:0000244|PDB:2NPH}.
FT   STRAND      520    523       {ECO:0000244|PDB:1A30}.
FT   STRAND      531    537       {ECO:0000244|PDB:2NPH}.
FT   STRAND      540    554       {ECO:0000244|PDB:2NPH}.
FT   STRAND      557    567       {ECO:0000244|PDB:2NPH}.
FT   STRAND      569    573       {ECO:0000244|PDB:1ODW}.
FT   HELIX       575    578       {ECO:0000244|PDB:2NPH}.
FT   HELIX       579    581       {ECO:0000244|PDB:2NPH}.
FT   STRAND      584    586       {ECO:0000244|PDB:2NPH}.
FT   STRAND      599    602       {ECO:0000244|PDB:1RTJ}.
FT   HELIX       615    630       {ECO:0000244|PDB:3QIP}.
FT   STRAND      633    636       {ECO:0000244|PDB:3QIP}.
FT   STRAND      639    641       {ECO:0000244|PDB:2RF2}.
FT   STRAND      647    651       {ECO:0000244|PDB:3QIP}.
FT   TURN        653    656       {ECO:0000244|PDB:3LAK}.
FT   STRAND      658    662       {ECO:0000244|PDB:3QIP}.
FT   HELIX       665    670       {ECO:0000244|PDB:3QIP}.
FT   HELIX       672    676       {ECO:0000244|PDB:3QIP}.
FT   TURN        677    679       {ECO:0000244|PDB:3QIP}.
FT   HELIX       684    686       {ECO:0000244|PDB:3QIP}.
FT   HELIX       687    689       {ECO:0000244|PDB:3QIP}.
FT   STRAND      691    697       {ECO:0000244|PDB:3QIP}.
FT   TURN        699    701       {ECO:0000244|PDB:3QIP}.
FT   HELIX       702    704       {ECO:0000244|PDB:3QIP}.
FT   STRAND      705    707       {ECO:0000244|PDB:1EP4}.
FT   HELIX       709    715       {ECO:0000244|PDB:3QIP}.
FT   STRAND      717    719       {ECO:0000244|PDB:3QIP}.
FT   HELIX       722    724       {ECO:0000244|PDB:3QIP}.
FT   STRAND      725    727       {ECO:0000244|PDB:1VRU}.
FT   STRAND      729    735       {ECO:0000244|PDB:3QIP}.
FT   HELIX       743    761       {ECO:0000244|PDB:3QIP}.
FT   STRAND      762    765       {ECO:0000244|PDB:1C0T}.
FT   STRAND      766    770       {ECO:0000244|PDB:3QIP}.
FT   STRAND      773    778       {ECO:0000244|PDB:3QIP}.
FT   HELIX       782    798       {ECO:0000244|PDB:3QIP}.
FT   HELIX       806    808       {ECO:0000244|PDB:3QIP}.
FT   STRAND      812    816       {ECO:0000244|PDB:3QIP}.
FT   STRAND      819    821       {ECO:0000244|PDB:3QIP}.
FT   HELIX       823    825       {ECO:0000244|PDB:3QIP}.
FT   STRAND      826    828       {ECO:0000244|PDB:3QIP}.
FT   STRAND      837    840       {ECO:0000244|PDB:1RTH}.
FT   HELIX       841    854       {ECO:0000244|PDB:3QIP}.
FT   TURN        855    857       {ECO:0000244|PDB:3QIP}.
FT   STRAND      858    860       {ECO:0000244|PDB:1JLG}.
FT   HELIX       864    869       {ECO:0000244|PDB:3QIP}.
FT   TURN        870    872       {ECO:0000244|PDB:3QIP}.
FT   STRAND      876    879       {ECO:0000244|PDB:2YNI}.
FT   HELIX       884    896       {ECO:0000244|PDB:3QIP}.
FT   STRAND      902    904       {ECO:0000244|PDB:1JLG}.
FT   STRAND      908    910       {ECO:0000244|PDB:4NCG}.
FT   STRAND      913    918       {ECO:0000244|PDB:3QIP}.
FT   STRAND      920    922       {ECO:0000244|PDB:3QIP}.
FT   STRAND      924    931       {ECO:0000244|PDB:3QIP}.
FT   STRAND      935    941       {ECO:0000244|PDB:3QIP}.
FT   STRAND      945    949       {ECO:0000244|PDB:3QIP}.
FT   HELIX       951    970       {ECO:0000244|PDB:3QIP}.
FT   STRAND      975    980       {ECO:0000244|PDB:3QIP}.
FT   HELIX       982    991       {ECO:0000244|PDB:3QIP}.
FT   STRAND      992    995       {ECO:0000244|PDB:3QIP}.
FT   STRAND     1000   1003       {ECO:0000244|PDB:3QIP}.
FT   HELIX      1008   1013       {ECO:0000244|PDB:3QIP}.
FT   STRAND     1024   1033       {ECO:0000244|PDB:3QIP}.
FT   TURN       1035   1037       {ECO:0000244|PDB:3QIP}.
FT   STRAND     1039   1046       {ECO:0000244|PDB:3QIP}.
FT   STRAND     1047   1049       {ECO:0000244|PDB:3DRP}.
FT   STRAND     1051   1058       {ECO:0000244|PDB:3QIP}.
FT   HELIX      1061   1074       {ECO:0000244|PDB:3QIP}.
FT   STRAND     1078   1084       {ECO:0000244|PDB:3QIP}.
FT   HELIX      1087   1094       {ECO:0000244|PDB:3QIP}.
FT   STRAND     1098   1102       {ECO:0000244|PDB:3QIP}.
FT   HELIX      1103   1114       {ECO:0000244|PDB:3QIP}.
FT   STRAND     1116   1122       {ECO:0000244|PDB:3QIP}.
FT   STRAND     1125   1127       {ECO:0000244|PDB:3LP1}.
FT   HELIX      1130   1139       {ECO:0000244|PDB:3QIP}.
FT   TURN       1140   1142       {ECO:0000244|PDB:3QIP}.
FT   HELIX      1204   1206       {ECO:0000244|PDB:1EXQ}.
FT   STRAND     1207   1215       {ECO:0000244|PDB:1EXQ}.
FT   STRAND     1218   1225       {ECO:0000244|PDB:1EXQ}.
FT   TURN       1226   1228       {ECO:0000244|PDB:1EXQ}.
FT   STRAND     1231   1240       {ECO:0000244|PDB:1EXQ}.
FT   HELIX      1241   1254       {ECO:0000244|PDB:1EXQ}.
FT   STRAND     1259   1261       {ECO:0000244|PDB:1EXQ}.
FT   HELIX      1266   1268       {ECO:0000244|PDB:1EXQ}.
FT   HELIX      1271   1280       {ECO:0000244|PDB:1EXQ}.
FT   HELIX      1302   1312       {ECO:0000244|PDB:1EXQ}.
FT   HELIX      1313   1315       {ECO:0000244|PDB:1EXQ}.
FT   HELIX      1319   1332       {ECO:0000244|PDB:1EXQ}.
FT   STRAND     1335   1339       {ECO:0000244|PDB:1EXQ}.
FT   HELIX      1343   1355       {ECO:0000244|PDB:1EXQ}.
FT   HELIX      1358   1368       {ECO:0000244|PDB:1EX4}.
FT   STRAND     1370   1374       {ECO:0000244|PDB:1EX4}.
FT   STRAND     1383   1391       {ECO:0000244|PDB:1EX4}.
FT   STRAND     1393   1399       {ECO:0000244|PDB:1EX4}.
FT   STRAND     1404   1408       {ECO:0000244|PDB:1EX4}.
FT   HELIX      1409   1411       {ECO:0000244|PDB:1EX4}.
FT   STRAND     1412   1414       {ECO:0000244|PDB:1EX4}.
SQ   SEQUENCE   1435 AA;  162042 MW;  8487B36BDEAC5FE4 CRC64;
     MGARASVLSG GELDRWEKIR LRPGGKKKYK LKHIVWASRE LERFAVNPGL LETSEGCRQI
     LGQLQPSLQT GSEELRSLYN TVATLYCVHQ RIEIKDTKEA LDKIEEEQNK SKKKAQQAAA
     DTGHSNQVSQ NYPIVQNIQG QMVHQAISPR TLNAWVKVVE EKAFSPEVIP MFSALSEGAT
     PQDLNTMLNT VGGHQAAMQM LKETINEEAA EWDRVHPVHA GPIAPGQMRE PRGSDIAGTT
     STLQEQIGWM TNNPPIPVGE IYKRWIILGL NKIVRMYSPT SILDIRQGPK EPFRDYVDRF
     YKTLRAEQAS QEVKNWMTET LLVQNANPDC KTILKALGPA ATLEEMMTAC QGVGGPGHKA
     RVLAEAMSQV TNSATIMMQR GNFRNQRKIV KCFNCGKEGH TARNCRAPRK KGCWKCGKEG
     HQMKDCTERQ ANFLREDLAF LQGKAREFSS EQTRANSPTR RELQVWGRDN NSPSEAGADR
     QGTVSFNFPQ VTLWQRPLVT IKIGGQLKEA LLDTGADDTV LEEMSLPGRW KPKMIGGIGG
     FIKVRQYDQI LIEICGHKAI GTVLVGPTPV NIIGRNLLTQ IGCTLNFPIS PIETVPVKLK
     PGMDGPKVKQ WPLTEEKIKA LVEICTEMEK EGKISKIGPE NPYNTPVFAI KKKDSTKWRK
     LVDFRELNKR TQDFWEVQLG IPHPAGLKKK KSVTVLDVGD AYFSVPLDED FRKYTAFTIP
     SINNETPGIR YQYNVLPQGW KGSPAIFQSS MTKILEPFRK QNPDIVIYQY MDDLYVGSDL
     EIGQHRTKIE ELRQHLLRWG LTTPDKKHQK EPPFLWMGYE LHPDKWTVQP IVLPEKDSWT
     VNDIQKLVGK LNWASQIYPG IKVRQLCKLL RGTKALTEVI PLTEEAELEL AENREILKEP
     VHGVYYDPSK DLIAEIQKQG QGQWTYQIYQ EPFKNLKTGK YARMRGAHTN DVKQLTEAVQ
     KITTESIVIW GKTPKFKLPI QKETWETWWT EYWQATWIPE WEFVNTPPLV KLWYQLEKEP
     IVGAETFYVD GAANRETKLG KAGYVTNRGR QKVVTLTDTT NQKTELQAIY LALQDSGLEV
     NIVTDSQYAL GIIQAQPDQS ESELVNQIIE QLIKKEKVYL AWVPAHKGIG GNEQVDKLVS
     AGIRKVLFLD GIDKAQDEHE KYHSNWRAMA SDFNLPPVVA KEIVASCDKC QLKGEAMHGQ
     VDCSPGIWQL DCTHLEGKVI LVAVHVASGY IEAEVIPAET GQETAYFLLK LAGRWPVKTI
     HTDNGSNFTG ATVRAACWWA GIKQEFGIPY NPQSQGVVES MNKELKKIIG QVRDQAEHLK
     TAVQMAVFIH NFKRKGGIGG YSAGERIVDI IATDIQTKEL QKQITKIQNF RVYYRDSRNP
     LWKGPAKLLW KGEGAVVIQD NSDIKVVPRR KAKIIRDYGK QMAGDDCVAS RQDED
//
